PF-[ADDRESS_780333] 
CROSSOVER STUDY EVALUATING THE ABUSE POTENTIAL OF THREE DOSES 
OF NEURONTIN® TAKEN ORALLY IN HEALTHY, NON-DRUG DEPENDENT 
PARTICIPANTS WITH SEDATIVE DRUG ABUSE EXPERIENCE 
Investigation al Product Number: PF-[ADDRESS_780334] Name: [CONTACT_591856]® (ga bapentin) 
[LOCATION_002] (US) Investigational New Drug 
Application (IND) Number:  28,454 and 57,813 
European Clinical Trials Database (EudraCT) 
Number:  Not Applicable (N/A) 
Protocol Number: A9451181 
Version Number 5.0 
Phase: 4 
Short Title:  Eva luating the Abuse Potential of Neurontin® When Taken Ora lly in Healthy Non-drug 
Dependent  Pa rticipants with Sedative Drug Abuse Experience 
Sponsor: Viatris Specialty LLC 
[ADDRESS_780335]   
Morgantown, WV [ZIP_CODE]  
Sponsor Contacts: 
This document and accompanying materials contain confidential i nformation belonging to  Viatris Specialty 
LLC.  Except as otherwise agreed to in writing, by [CONTACT_591815] g t h ese d ocument s, y o u agree t o  h old  
this information in confidence and not copy or disclose it to o thers (except where required by a pplicable la w) or 
use it for unauthorized purposes.  In the event of any actual o r suspected breach of this obliga tion, Via tris 
Specialty LLC must be promptly notified. 
Study ID: [REMOVED]
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 2 PROTOCOL APPROVAL – SPONSOR SIGNATORY 
Study Title  A phase 4, randomized, double-blind, double-dummy, placebo- and  
active -controlled, single-dose, five- way crossover study evaluating 
the Abuse Potential of three Doses of Neurontin® taken orally in 
healthy, non -drug dependent participants with sedative drug abuse 
experience  
Protocol Number  A9451181  
V ersion No.  5.0  
Protocol Date  29 Apr 2022  
 
Protocol accepted and approved by:  
 
 [CONTACT_591816]-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 3 Protocol Amendment Summary of Changes Table 
Document History 
Document Version 
Date Summary of Changes and Rationale 
Protocol 
Version 5.0 29 Apr 2022 x Change of Sponsor name [CONTACT_591857] 1 LLC to 
Viatris Specialty LLC 
x Increasing the number of subjects enrolled 
x Modifying the definition of the Completer Population 
(upon which other analysis sets are defined) to 
specify the minimum required post- dose responses 
required within the Tmax time periods specific to the 
two study drugs, in line with FDA guidance on 
assessing abuse potential of drugs 
x Addition of the Modified Completer Population as 
the primary analysis population 
x Clarification that the Evaluation Population will be 
the subset of the Modified Completer Population who 
do not have major protocol deviations 
x Redefining the permitted time wi ndows for vital sig ns 
assessments and PK sampling 
x Reducing the number of residential nights from 4 to 3 
per treatment period , at the investigator’s discretion,  
to facilitate subject enrollment 
x Adding “multi -center” in the study description  
x Clarification that subjects must abstain from using 
THC while resident in the clinic  
x Addition of further forms of acceptable female 
contraception 
x Clarifications and corrections to the statistics sections 
with respect to the null- and alternative- hypothesis 
equations, handling of missing pre- dose VAS values, 
and addition of “site” as a fixed effect  
x Updating the time period for making trial data 
available to reflect the change of Sponsor 
Complete summary of changes is provided in Appendix 
13 (Section 10.13)  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 4 Protocol 
Version 4.0 04 Aug 2021 x Modified three inclusion/exclusion criteria, including 
the de finition of an experienced recreational sedative 
user, in order to facilitate subject enrolment. 
x Administrative changes to update Sponsor contact 
[CONTACT_591817] 13 
 
Complete summary of changes is provided in Appendix 
13 (Section 10.13) 
 
Protocol 
Version 3.0 26 Feb 2021 x Couple of typographic changes for harmonization 
within the protocol were implemented.  
 
Complete summary of changes is provided in 
Appendix 10.13 
Protocol 
Version 2.0 11 Dec 2020 x The sponsor for this study is changed from ‘[COMPANY_007]’ to 
‘Upjohn US 1 LLC’  
x The responsib ility of an Interactive Response 
Technology (IRT) was transferred to a CRO. 
x Administrative and typographic changes for 
harmonization within the protocol were implemented. 
Complete summary of changes is provided in 
Appendix 10.13 
Original 
Protocol 14 May 2020 Not applicable (N/A) 
PF-[ADDRESS_780336] OF FIGURES ..........................................................................................................10  
1. PROTOCOL SUMMARY.............................................................................................11
1.1. Synopsis (Not Applicable) ................................................................ .................1 1 
1.2. Schema .............................................................................................................11  
1.3. Schedule of Activities (SoA) ............................................................... ..............12  
2. INTRODUCTION ........................................................................................................18
2.1. Study Rationale .................................................................................................18  
2.2. Background ......................................................................................................18  
2.2.1. Clinical Overview ...................................... ...........................................19  
2.3. Benefit/Risk Assessment ...................................................................................19  
3. OBJECTIVES AND ENDPOINTS.................................... ............................................20
4. STUDY DE SIGN ............................................... ..........................................................21
4.1. Overall Design ..................................................................................................21  
4.1.1. Screening ..............................................................................................22  
4.1.2. Qualification Phase (Visit 2; Days -1 to 3)..............................................22  
[IP_ADDRESS]. Naloxone Challenge (Day -1) .......................... ......................22  
[IP_ADDRESS]. Instrument Training...............................................................23  
[IP_ADDRESS]. Drug Discrimination (Days 1 to 3) .........................................23  
4.1.3. Treatment Phase (Visits 3 to 7) ..............................................................24  
4.2. Scientific Rationale for Study Design.................................................................24  
4.3. Justification for Dose.........................................................................................25  
4.4. End of Study Definition .....................................................................................25  
5. STUDY POPU LATION............................................ ....................................................25
5.1. Inclusion Criteria ..............................................................................................26  
5.2. Exclusion Criteria .............................................................................................27  
5.3. Lifestyle Considerations ....................................................................................29  
5.3.1. Meals and Dietary Restrictions ..............................................................29  
5.3.2. Caffeine, Alcohol, and Tobacco .............................................................30  
5.3.3. Activity.................................................................................................30  
5.3.4. Contraception ........................................................................................30  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
Viatris Specialty LLC CONFIDENTIAL 
Page 6 5.4. Screen Failures..................................................................................................31  
6. STUDY INTER VENTION ......................................... ..................................................31
6.1. Study Interventions Administered ......................................................................31  
6.1.1. Administration ......................................................................................31  
6.2. Preparation/Handling/Storage/Accountability .....................................................31  
6.2.1. Preparation and Dispensing....................................................................32  
6.3. Measures to Minimize Bias: Randomization and Blinding .... ..............................[ADDRESS_780337] .....................................................33  
6.3.2. Breaking the Blind ................................................................................33  
6.4. Study Intervention Compliance............................. .............................................34  
6.5. Concomitant Therapy ........................................................................................34  
6.6. Dose Modification.............................................................................................34  
6.7. Emergency Intervention ................................... .................................................34  
6.8. Intervention After the End of the Study ..............................................................35  
7. DISCONTINUATION OF STUDY INTERVENTION AND PART ICIPANT
DISCONTINUATION/WITHDRAWAL ......................................................................35  
7.1. Discontinuation of Study Intervention ................................................................35  
7.2. Participant Discontinuation/Withdrawal from the Study .... .................................[ADDRESS_780338] to Follow up ..............................................................................................37  
8. STUDY ASSESSMENTS  AND PROCE DURES ........................... ................................38
8.1. Efficacy Assessments (Not applicable)..................... ..........................................39  
8.2. Safety Assessments ...........................................................................................39  
8.2.1. Physical Examinations...........................................................................39  
8.2.2. Vital Signs ............................................................................................39  
[IP_ADDRESS]. Respi[INVESTIGATOR_591788] .........................................................40  
[IP_ADDRESS]. Temperature..........................................................................40  
8.2.3. Electrocardiograms................................................................................40  
[IP_ADDRESS]. Continuous Cardiac Monitoring by [CONTACT_336258]........................41  
8.2.4. Clinical Safety Laboratory Assessments .................................................41  
8.2.5. Suicidal Ideation and Behavior Risk Monitoring.......... ...........................42  
[IP_ADDRESS]. Columbia Suicidality Severity Rating Scale (C-SSRS) .. .........42  
[IP_ADDRESS]. Risk Assessment During Screening...................... ..................42  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 7 [IP_ADDRESS]. Risk Assessment During the Study ..................... ...................43  
8.2.6. Pregnancy Testing ...................................... ...........................................43  
8.3. Adverse Events and Serious Adverse Events ......................................................43  
8.3.1. Time Period and Frequency for Collecting AE and SAE Info rmation ......44  
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...................... ......................44  
[IP_ADDRESS]. Recording Non-serious AEs and SAEs on the CRF ................45  
8.3.2. Method of Detecting AEs and SAEs.......................................................45  
8.3.3. Follow-up of AEs and SAEs ..................................................................45  
8.3.4. Regulatory Reporting Requirements for SAEs ............. ...........................45  
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational 
Exposure ....................................................................................................46  
[IP_ADDRESS]. Exposure During Pregnancy ..................................................46  
[IP_ADDRESS]. Exposure During Breastfeeding ........................ .....................48  
[IP_ADDRESS]. Occupational Exposure..........................................................48  
8.3.6. Cardiovascular and Death Events ...........................................................49  
8.3.7. Disease-Related Events and/or Disease-Related Outcomes N ot 
Qualifying as AEs or SAEs.........................................................................[ADDRESS_780339] .........................................................49  
[IP_ADDRESS]. Lack of Efficacy ...................................................................49  
8.3.9. Medical Device Deficiencies .................................................................49  
8.3.10. Medication Errors................................................................................49  
8.4. Treatment of Overdose ......................................................................................50  
8.5. Pharmacokinetics ..............................................................................................50  
8.6. Pharmacodynamics ...........................................................................................51  
8.6.1. Subjective Effects..................................................................................51  
8.6.2. Visual Analog Scale (VAS) ....................................................................51  
8.7. Genetics............................................................................................................52  
8.7.1. Specified Genetics ..................................... ............................................52  
8.7.2. Banked Biospecimens for Genetics ....................... .................................52  
8.8. Biomarkers .......................................................................................................52  
8.9. Health Economics .............................................................................................53  
9. STATISTICAL CONSIDERATIONS ...........................................................................53  
9.1. Statistical Hypotheses........................................................................................53  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 8 9.2. Sample Size Determination................................................................................54  
9.3. Populations for Analysis....................................................................................54  
9.4. Statistical Analyses ...........................................................................................55  
9.5. Interim Analyses ...............................................................................................55  
9.6. Endpoint Analysis .............................................................................................55  
9.7. Study Validity Analysis of Endpoints.................................................................56  
9.8. Analysis of Primary and Secondary Endpoints ...................................................56  
9.8.1. Pharmacodynamic Analysis ............................... ....................................57  
9.8.2. Derivation of Pharmacodynamic Parameters ............... ...........................58  
9.8.3. Pharmacokinetic Analysis......................................................................58  
[IP_ADDRESS]. Pharmacokinetic Parameters ..................................................59  
[IP_ADDRESS]. Derivation of Pharmacokinetic Parameters .............................59  
9.9. Efficacy Analyses .............................................................................................60  
9.10. Safety Analyses...............................................................................................60  
9.10.1. Electrocardiogram Analyses.................................................................60  
9.11. Exploratory Analyses ......................................................................................60  
9.12. Data Monitoring Committee ............................................................... .............61  
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ...................................................................................................62  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Cons iderations ..............62  
10.1.1. Regulatory and Ethical Considerations ................. ................................62  
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP ....................................................................62  
10.1.2. Financial Disclosure ............................................................................63  
10.1.3. Informed Consent Process....................................................................63  
10.1.4. Data Protection....................................................................................64  
10.1.5. Dissemination of Clinical Study Data .................. .................................64  
10.1.6. Data Quality Assurance ............................................................... ........66  
10.1.7. Source Documents...............................................................................67  
10.1.8. Study and Site Closure.........................................................................67  
10.1.9. Publication Policy................................................................................67  
10.1.10. Sponsor’s Qualified Medical Personnel  ..............................................68  
10.2. Appendix 2: Clinical Laboratory Tests ................... ..........................................69  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 9 10.3. Appendix 3: Adverse Events: Definitions and Procedures fo r Recording, 
Evaluating, Follow-up, and Reporting ..................................................................71  
10.3.1. Definition of AE ..................................................................................71  
10.3.2. Definition of SAE ............................................................... .................72  
10.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs .. ...................73  
10.3.4. Reporting of SAEs...............................................................................76  
10.4. Appendix 4: Contraceptive Guidance and Collection of Preg nancy 
Information .........................................................................................................78  
10.4.1. Male Participant Reproductive Inclusion Criteria ...... ............................78  
10.4.2. Female Participant Reproductive Inclusion Criteria .... ..........................78  
10.4.3. Woman of Childbearing Potential (WOCBP)................ ........................79  
10.4.4. Contraception Methods ........................................................................79  
10.5. Appendix 5: Genetics ......................................................................................82  
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up  Assessments........83  
10.7. Appendix 7: ECG Findings of Potential Clinical Concern .. ...............................85  
10.8. Appendix 8: Clinical Opi[INVESTIGATOR_591789] ...................................................87  
10.9. Appendix 9: Abbreviations ............................... ...............................................88  
10.10. Appendix 10: VAS Assessment Methods .......................................................91  
10.11. Alertness/Sedation Assessment ......................................................................94  
10.12. Appendix 12: Alternative Measures During Public Emergenc ies .....................95  
10.12.1. Eligibility ..........................................................................................95  
10.12.2. Telehealth Visits..................................... ...........................................95  
10.12.3. Alternative Facilities for Safety Assessments ......................................95  
10.12.4. Study Intervention .............................................................................95  
10.12.5. Home Health Visits ...........................................................................95  
10.12.6. Adverse Events and Serious Adverse Events ............ ..........................95  
10.12.7. Efficacy Assessments ........................................................................95  
10.12.8. Independent Oversight Committees ..................... ...............................95  
10.13. Appendix 13: Summary of Changes ...............................................................[ADDRESS_780340] OF TABLES 
Table 1.  Schedule of Activities for Screening, Naloxone Challenge and 
Qualification Phase..............................................................................12  
Table 2.  Schedule of Activities for Treatment Phase ..........................................15  
Table 3.  Schema for Qualification Phase............................................................23  
Table 4.  Derivation of Pharmacodynamic Parameters....................... ..................58  
Table 5.  Derivation of Pharmacokinetic Parameters ...................... .....................59  
Table 6.  Protocol-Required Safety Laboratory Tests ..................... .....................69  
Table 7.  Other Subjective Effects Visual Analog Scales .....................................93  
Table 8.  Modified Observer’s Assessment of Alertness/Sedation Scale ...............[ADDRESS_780341] OF FIGURES 
Figure 1.  Schematic of Study Visits ....................................................................11  
 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 11 1. PROTOCOL SUMMARY 
1.1. Synopsis (Not Applicable) 
1.2. Schema 
The participants will be screened, undergo a naloxone challenge  to ensure that they are not 
drug dependent and a drug discrimination test to demonstrate th at they can differentiate 
between a positive control and pl acebo.  Once the participant has passed these tests, they may 
be enrolled into the Treatment Phase of the study.  The Treatme nt Phase of the study will use 
a Williams square st udy design involving approximately 50 participants (5 participa nts in 
each sequence) to ensure at least 32 participants meeting the d efinition of the Modified 
Completer Population complete the treatment phase of the study as shown in Figure 1.  Drop-
out participants in the treatment phase for non-safety reasons may be replaced at the 
discretion of investigator in consultation with the sponsor. 
Figure 1. Schematic of Study Visits 
 

PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 12 1.3. Schedule of Activities (SoA) 
The SoA tables (Table 1 and Table 2) provide an overview of the  protocol visits and procedures.  Refer to the STUDY 
ASSESSMENTS AND PROCEDURES section of the protocol for detailed information  on each procedure and assessment required 
for compliance with the protocol.  The investigator may schedul e visits (unplanned visits) in addition to those listed in the SoA table, 
to conduct evaluations or assessments required to protect the w ell-being of the participant.  
Table 1. Schedule of Activities for Screen ing, Naloxone Challenge and Qu alification Phase  
 Visit 1 
Screening 
 Visit 2 (Qualification Phase) 
Naloxone 
Challenge Drug Discrimination 
Study Day Within [ADDRESS_780342] Dose   Pre-dose 0 0.25 0.5 1 1.5 2 2.5 3 3.5 4 5 24 
Clinical Research Unit (CRU) 
admission  Xa o o o o o o o o o o o o  
Informed consent Xb               
Inclusion/Exclusion X               
Demographics X               
Medical history (including drug 
abuse) X X              
Ongoing eligibility review X X             X 
Prior/Concomitant medication 
(including past year recreational 
drug history)  X o o o o o o o o o o o o o o 
Physical examinationc X X             X 
Safety laboratory tests X X              
HIV, HBsAg, HBcAb, HCVAb, 
HAV IgM, HAV IgG X               
Urine drug testing X X              
Serum Pregnancy test (Woman Of 
Childbearing Potential [ WOCBP ] 
only) Xd               
Follicular stimulating hormone 
(FSH) testing Xe               
Urine Pregnancy test (WOBCP 
only)  Xf              
Contraception check X               
Alcohol breathalyzer X X              
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 13 Table 1. Schedule of Activities for Screen ing, Naloxone Challenge and Qu alification Phase  
 Visit 1 
Screening 
 Visit 2 (Qualification Phase) 
Naloxone 
Challenge Drug Discrimination 
Study Day Within 28 
Days  Day -1 Days 1 and 2 Day 3p 
Vital signsg X Xh X  X X X X X       
Pulse oximetry, SpO 2   X  X X X X X X X X X X  
Respi[INVESTIGATOR_697]   X  X X X X X X X X X X  
12-lead Electrocardiogrami X X              
Randomization for Qualification 
Phase, Day 1   X             
Pharmacodynamic (Instrument) 
training  X              
Cardiac telemetryj   X o o o o o o o o o o X  
Study treatment administered  Xk  X            
Visual Analogue Scales (VAS)l    Xl(a)  X X X X X X X X X X  
Take Drug Again, VAS, Overall 
“Drug  
Liking”               X  
Clinical Opi[INVESTIGATOR_2433] 
(COWS)  Xm              
Serious and non-serious adverse 
event monitoringn X X o o o o o o o o o o o o X 
Columbia Suicide-Severity Rating 
Scale X X             X 
Evaluate to proceedo  X             X 
Discharge from CRU               X 
Abbreviations: COWS = Clinical Opi[INVESTIGATOR_2433]; CRU = C linical Research Unit; FSH = follicle stimulating hormone; HAV  IgG = hepatitis A virus 
immunoglobulin G; HAV IgM = hepatitis  A virus imm unoglobulin M; HBsAg = hepa titis B surf ace antigen; HCVab  = hepatitis C anti body; HIV = human 
immunodeficiency virus; SpO 2 = saturated oxygen; VAS = Visual Analogue Scale; WOCBP = women  of childbearing potential. 
a. Admission should occur in the morning to ensure adequate time f or pre-dose review of clinical laboratory results. 
b. Assign a single participant identifier number.  
c. Complete physical examination (PE) (including height and weight ) only needs to be done once, ie, at Screening or at Day -[ADDRESS_780343] be performed at Screening to obtain BMI for determination of eligibility .  A brief symptom- directed physical examination will be c onducted as needed on Day -1 
and prior to discharge on Day 3. 
d. Review of results are required prior to dosing on Visit 2 (ie, Naloxone Challenge). 
e. For confirmation of postmenopausal status only.  
f. Must be reviewed and confirmed as negative prior to dosing on D ay -1. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 14 Table 1. Schedule of Activities for Screen ing, Naloxone Challenge and Qu alification Phase  
 Visit 1 
Screening 
 Visit 2 (Qualification Phase) 
Naloxone 
Challenge Drug Discrimination 
Study Day Within 28 
Days  Day -1 Days 1 and 2 Day 3p 
g. Includes pulse rate, systolic and diastolic blood pressures.  T emperature (oral or with a temporal infrared scanner) will be m easured at Screening and upon admission on 
Day -1 of the Naloxone Challenge Phase.  Vital signs are measur ed after a resting period of approximately 5 minutes in a sitti ng position. 
h. Vital signs will be recorded at pre-dose (first nal oxone dose) and at 5 minutes, 0.25, 0.5, 1, 1.5, and 2 hours fo llowing the second dose of naloxone. Vital signs will be 
recorded at nominal time points ± [ADDRESS_780344] 10 minutes in a su pi[INVESTIGATOR_2547] . 
j. Continuous cardiac telemetry (heart rate, cardiac rhythm, and o xygen saturation) will be monitored for approximately [ADDRESS_780345]- dose or longer at the discretion of the 
clinical research unit. 
k. Naloxone (0.2 mg IV) is administered first.  If there are no si gns of withdrawal apparent within 30 seconds after administrati on, another 0.6 mg naloxone IV is 
administered. 
l. Include VASs for Drug Liking, High, Sleepy, Dizzy, Nausea, and Feel Sick. 
l(a); Only for High, Sleepy, Dizzy, Nausea, and Feel Sick are a dministered at pre-dose. 
m. COWS is collected and recorded at pre-dose, and at [ADDRESS_780346] naloxone dose and 5 minutes after the second  dose is administered.  
n. Assessed throughout and collected using open-ended questions.  Symptoms of withdrawal following naloxone administration (Nalox one Challenge Phase) will not be 
collected as adverse events unless they meet the criteria for a n SAE.  Adverse events and serious AEs will be collected from the time the informed consent is signed 
through and including [ADDRESS_780347] occur prior to next scheduled time a nd event.  
p. If participants fail to qualify, all AEs will be reported with no further SoA testing.  
 
 
 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 15 Table 2. Schedule of Activities for Treatment Phase 
Study Day Visits 3 to 7 
Treatment Phase 
Periods 1 to 5a Follow-up Early 
termination/discontinuation 
(DC) 
Day -[ADDRESS_780348] (WOCBP 
only)f X                     
Serum Pregnancy test (WOCBP 
only)f                   Xm  X 
Contraception check X                   X X 
Alcohol breathalyzer X                     
Vital signsg X X  X X X X X X X X X X X X X X X X  X 
Pulse oximetry, SpO 2  X o o o o o o o o o o o o X X     X 
Respi[INVESTIGATOR_697]  X o o o o o o o o o o o o X X      
Tidal volume  X o o o o o o o o o o o o X X      
End-tidal carbon dioxide  X o o o o o o o o o o o o X X      
Randomization  Xh                    
Pharmacodynamic (Instrument) 
training X                     
Cardiac telemetryi  X o o o o o o o o o o o o        
Study treatment administration   X                   
VASj  Xj (a)  X X X X X X X X X X X X X X X X  X 
VAS for Overall Drug Liking and 
“Take Drug Again ”                X X X X  X 
VAS for Good Drug Effect, Bad 
Drug Effect, and Any Drug Effect    X X X X X X X X X X X X X X X X  X 
Observer-rated assessment of 
alertness/sedation  X  X X X X X X X X X X X X X X X X  X 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 16 Table 2. Schedule of Activities for Treatment Phase 
Study Day Visits 3 to 7 
Treatment Phase 
Periods 1 to 5a Follow-up Early 
termination/discontinuation 
(DC) 
Day -[ADDRESS_780349] Dose  Pre-dose 0 0.25 0.5 1 1.5 2 2.5 3 3.5 4 6 8 12 24 36 48 72   
Viatris Prep D1 Banked 
biospecimenk X                     
Pharmacokinetic blood sampling  X   X X X X X X X X X X X X X X X X  X 
Serious and non-serious adverse 
event monitoringl X X o o o o o o o o o o o o o o o o o X X 
Columbia Suicide-Severity Rating 
Scale X                  X X X 
ECGo X                  X   
Discharge from CRU                  Xp X   
Discharge from Study                    X  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 17 Table 2. Schedule of Activities for Treatment Phase 
Study Day Visits 3 to 7 
Treatment Phase 
Periods 1 to 5a Follow-up Early 
termination/discontinuation 
(DC) 
Day -[ADDRESS_780350], pregnancy tests, compliance with Lifestyle gui delines, and any changes to medical conditions 
that may require participant rescheduling or discontinuation.  
c. Physical examinations will be brief and symptom-directed (if a change in medical history is reported).  Symptom-directed  physical examinations may be performed at 
admission to each visit at the discretion of the Investigator.  A complete physical examination w ill be c onducted at End of Study or early termination (ET). 
d. See Appendix [ADDRESS_780351] will be obtained at the End of Study 
Visit. 
g. Vital signs (including pulse rate, systolic and diastolic blood  pressures are measured at the nominal time points after a resting period of a t least 5 minutes in a sitting position.  
Temperature (oral or with a temporal infrared scanner) will be measured on Day -1 of each Treatment Visit only. Vital signs wi ll be recorded at nominal time points ±[ADDRESS_780352]-dose, within ±[ADDRESS_780353]- dose, and within ±[ADDRESS_780354]-dose. 
h. Visit 3 pre-dose only.  
i. Continuous cardiac telemetry (heart rate, cardiac rhythm, and o xygen saturation) will be monitored from pre-dose for approxima tely [ADDRESS_780355]-dose or longer at the 
discretion of the clinical research unit. 
j. Include VASs for Drug Liking, High, Sleepy, Dizzy, Nausea, and Feel Sick. 
J(a); Only VASs for High, Sleepy, Dizzy, Nausea, and Feel Sick are administered at pre-dose.  
k. Visit [ADDRESS_780356] at the next available time point when biospecimens are being collected in 
conjunction with a participant visit.  
l. Spontaneous AE reporting w ill occur throug hout study; however, AEs w ill also be elicited using non -leading questions during the Tre atment Phase at pre-dose and post- dose 
at the indicated times.  AEs and SAEs will be collected from th e time the informed consent is signed through and including [ADDRESS_780357].  
o. 12-lead Electrocardiogram measurements (conducted after a resti ng period of at least 10 minutes in a supi[INVESTIGATOR_2547]) at Day - 1 (baseline) and Day 4 during Treatment P hase 
p. Subjects may be discharged after completion of Day 3 assessment s and return for Day 4 assessments, at the discretion of the investigator. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 18 2. INTRODUCTION 
2.1. Study Rationale 
Neurontin® (gabapentin)  is indicated for postherpetic neuralgia in adults, adjunctive therapy 
in the treatment of partial onset seizures, with and without se condary generalization in adults 
and pediatric patients 3 years and older with epi[INVESTIGATOR_002]. 
Gabapentin does not exhibit affinity for benzodiazepi[INVESTIGATOR_050], opi[INVESTIGATOR_2573] (mu, delta or kappa), or 
cannabinoid 1 receptor sites; however, gabapentin abuse has bee n reported at increasing 
rates.   Individuals abusing gabapentin describe experiences such as eup horia, improved 
sociability, relaxation and a marijuana- like “high”.1-[ADDRESS_780358] abu se potential, particularly 
among individuals with a history of opi[INVESTIGATOR_2554].  Gabapentin a buse is reported both alone 
(ie, without other drugs), and in conjunction with opi[INVESTIGATOR_591790] e the ‘high’ obtained from 
opi[INVESTIGATOR_2438].1,[ADDRESS_780359]-authorization safety study (PASS) to evaluate 
gabapentin in a cross-over design with comparison to placebo an d a positive control, 
diazepam, regarding abuse-related subjective responses, physiol ogical responses (including 
an assessment of respi[INVESTIGATOR_2341]), and drug pharmacokine tics in a healthy non-drug 
dependent population with drug abuse experience with sedative d rugs.  
2.2. Background  
The precise mechanisms by [CONTACT_591818][INVESTIGATOR_591791].  Gabapentin is structurally related to the neurotr ansmitter gamma-aminobutyric 
acid (GABA) but has no effect on GABA binding, uptake, or degra dation.  In vitro studies 
have shown that gabapentin binds with high-affinity to the D2G subunit of voltage-activated 
calcium channels; however, the relationship of gabapentin binding to its therapeutic effects or potential abuse is unknown.  
Approximately 1.1% of the general population and 22% of those a ttending addiction 
facilities have a history of abuse of gabapentin
8,[ADDRESS_780360] been deaths from gabapentin 
use with benzodiazepi[INVESTIGATOR_199721].1-7  The purpose of the present study is to assess 
prospectively the abuse potential of gabapentin compared to pla cebo and diazepam. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 19 2.2.1.  Clinical Overview 
Neurontin® formulations are available in strengths of 100 mg, 300 mg, 400  mg capsules and 
600 mg and 800 mg tablets and in an oral solution containing 250 mg/5 mL of gabapentin.  
Gabapentin is rapi[INVESTIGATOR_549726].  Peak concentrations were 
observed within 2 to 3 hours.  Gabapentin bioavailability is not dose proportional; ie, as dos e is 
increased, bioavailability decreases.  Bioavailability of gabap entin is approximately 60%, 47%, 
34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in [ADDRESS_780361] on the rate and extent of absorption of 
gabapentin (14% increase in area under the curve [AUC] and maxi mum observed concentration 
[Cmax]).  Gabapentin is eliminated from the systemic circulation by r enal excretion as unchanged 
drug.  Gabapentin is not appreciably metabolized in humans.  Ga bapentin elimination half-life is 
5 to 7 hours and is unaltered by [CONTACT_591819].  Gabapentin elimination rate 
constant, plasma clearance, and renal clearance are directly pr oportional to creatinine clearance.10 
Valium® (diazepam) is indicated for the management of anxiety disorder s or for the 
short-term relief of the symptoms of anxiety.  After oral admin istration >90% of diazepam is 
absorbed and the average time to achieve peak plasma concentrat ions is 1 – 1.5 hours with a 
range of 0.25 to 2.5 hours.  Absorption is delayed and decrease d when administered with a 
moderate fat meal.  In the presence of food, mean lag times are  approximately 45 minutes as 
compared with 15 minutes when fasting.  Diazepam is N-demethyla ted by [CONTACT_13439] 
P450 (CYP)3A4 and 2C19 to the active metabolite N-desmethyldiaz epam and is 
hydroxylated by [CONTACT_097]3A4 to the active metabo lite temazepam.  N-desmethyldiazepam and 
temazepam are both further metabolized to oxazepam.  Temazepam and oxazepam are 
largely eliminated by [CONTACT_12075].[ADDRESS_780362] 25% to 33% of 
diazepam’s anticonvulsant activity.  As a result of extensive first-pass metabolism, the 
unchanged diazepam in the urine is only 1 –3%.12  The initial distribution phase is followed 
by a prolonged terminal elimination phase (half-life up to 48 h ours).  The terminal 
elimination half-life of the active metabolite N-desmethyldiaze pam is up to 100 hours.  
Diazepam and its metabo lites are excreted mainly in the urine, predominantly as their 
glucuronide conjugates.  The clearance of diazepam is 20 to 30 mL/min in young adults.  
2.3. Benefit/Risk Assessment 
Neurontin® and diazepam are not expected to provide any clinical benefit to healthy 
participants in this study.  This study is designed to assess t he effect of Neurontin® compared 
to diazepam when taken orally in healthy non-dependent recreational drug abusers on the 
pharmacokinetics of each drug and the potential for abuse.  
More detailed information about the known and expected benefits and risks and expected 
adverse events (AEs) of gabapentin and diazepam may be found in  the single reference safety 
document (SRSD) for this study.  The SRSDs for gabapentin and d iazepam are their 
respective [LOCATION_002] Package Inserts (USPI).10,11 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 20 3. OBJECTIVES AND ENDPOINTS 
Objectives Endpoints 
Primary:  Primary:  
x To a ssess the potential a buse lia bility of orally 
a dministered Neurontin® ta ken  alo ne 
compared to placebo in a healthy non- drug 
dependent participants with drug abuse 
experience under fasted condition. x Bipolar visual analog scale (VAS) for “Drug 
Liking” maximum effect (E max). 
Secondary:  Secondary:  
x To eva luate additional pharmacodynamic (PD) 
effect, pharmacokinetics (PK), and safety of 
Neurontin® or diazepam taken alone  in a  
healthy non- drug dependent participants with 
drug abuse experience under fasted condition. PD endpoints: 
x Bip o la r VAS f o r “Dru g Lik in g” ( Tim e f o r E max 
[TE max], area under the effect- t ime p rof ile f rom 
time [ADDRESS_780363] quantifiable 
concentration [AUEC last], a n d p art ial AUEC s 
[AUEC 1, AUEC 2, AUEC 3, AUEC 4, AUEC 8]). 
x Unipolar VAS for “High” ( Emax, TE max, 
AUEC last, and partial AUECs [AUEC 1, AUEC 2, 
AUEC 3, AUEC 4, AUEC 8]). 
x Bip o la r VAS f o r “Ta ke Dru g Aga in ” a t 24, 36, 
48, and [ADDRESS_780364]-dose. 
x Bip o la r VAS f o r “Ov era ll Dru g Lik in g” a t  24, 
36, 48, and [ADDRESS_780365]-dose. 
x Unipolar VAS f o r “ Good Drug Effect ”. 
x Unipolar VAS for “ Bad Drug Effect ”.  
x Unipolar VAS for “ Any Drug Effect ”.  
x Observer-rated a ssessment of alertness/sedation. 
PK endpoints:  
x Cmax, time for C max (Tmax), area under the 
effect- t ime p ro file f ro m t ime [ADDRESS_780366] qua ntifiable concentration (AUC last) of 
gabapentin and, if deemed necessary for 
diazepam and its active metabolite 
(N-desmethyldiazepam).  
x Area under the plasma concentration-time 
profile from time 0 extrapolated to infinity time 
(AUC inf), a nd terminal ha lf-life (t ½), if data 
permits, of ga bapentin a nd, if deemed necessary 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 21 Objectives Endpoints 
for diazepam and its active metabolite 
(N-desmethyldiazepam).  
x Pa rtia l AUCs (AUC 1, AUC 2, AUC 3, AUC 4, and 
AUC 8) of gabapentin and, if deemed necessary 
for diazepam and its active metabolite 
(N-desmethyldiazepam).  
Safety endpoints:  
x Vital signs (respi[INVESTIGATOR_697] [RR], blood pressur e 
[BP], pulse rate [PR]). 
x Oxygen saturation of hemoglobin (SpO 2). 
x Physical examination. 
x 12-lea d electrocardiogram (ECG). 
x Clin ica l la b  a n d AEs. 
Tertiary/Exploratory: Tertiary/Exploratory: 
x Exposure-response relationship between drug 
(gabapentin or diazepam) concentrations and 
selected PD effect. 
x To enable exploratory research through 
collection of banked biospecimens, unless 
prohibited by [CONTACT_168038].   x Correlation between drug (gabapentin or 
diazepam) concentrations and selected PD 
endpoints (Bipolar VAS f o r “Dru g Lik in g”, 
Un ip o la r VAS f o r “H igh ”), a s d ata p ermit .  
x Potential results from exploratory a nalysis of 
banked biospecimens (these results may or may 
not be generated in the context of the present 
study). 
4. STUDY DESIGN 
4.1. Overall Design 
This will be a multi-center, ra ndomized, double-blind, double-dummy, placebo- and 
active-controlled, 5-treatment, 10-sequence, 5-period crossover  single-dose, Williams square 
design study in healthy adult, non drug-dependent male and fema le participants with drug 
abuse experience with sedative drugs.  The study includes Scree ning, a Qualification Phase, a 
Treatment Phase and Follow-up.  This study w ill randomize approximately [ADDRESS_780367] 32 participants meeting the definition of the M odified Completer Population 
complete the Treatment Phase of the study.  Dropouts in the tre atment phase for non-safety 
reasons may be replaced at the discretion of investigator in co nsultation with the sponsor.   
The following study visits are required, see Figure 1 and the S oA (Table 1 and Table 2): 
x Visit 1, Screening will occur within 28 days prior to Visit 2. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 22 x Visit 2, Qualification Phase will require inpatient stay at the  clinical research unit 
(CRU) for 3 nights: 
x Naloxone Challenge Phase, Day -1. 
x Drug Discrimination, Days [ADDRESS_780368] 14 and no more than 28-day 
washout.  
x Visits 3 to 7, Treatment Phase: 
x Each visit will require an inpatient stay at the CRU of [ADDRESS_780369] 
study drug dosing at the end of period 5 or at the time of earl y withdrawal. 
x For the entire study, 18 - 23 overnight inpatient stays w ill be required.  
4.1.1.  Screening 
As shown in the SoA (Table 1), all participants will complete a  Screening Visit with a 
standard medical screening to determine eligibility for this st udy.  This visit (Visit 1) w ill 
occur within 28 days of the Qualification Phase of the study (V isit 2).  
4.1.2.  Qualification Phase (Visit 2; Days -1 to 3) 
[IP_ADDRESS].  Naloxone Challenge (Day -1) 
As shown in the SoA (Table 1), eligible participants who succes sfully complete the 
Screening Visit will return to the study center to complete the  naloxone challenge.  The 
naloxone challenge (Day -1) w ill be performed to ensure the participant is not physically 
dependent on opi[INVESTIGATOR_2438]. 
During the Naloxone Challenge, all participants w ill receive intravenous (IV) naloxone 
0.[ADDRESS_780370] signs and symptoms of opi[INVESTIGATOR_591792], as assessed by [CONTACT_591820]-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 23 Clinical Opi[INVESTIGATOR_9721] (COWS score <5), [ Appendix 8 ] will be eligible to 
proceed to the Drug Discrimination Phase. 
Any participant demonstrating evidence of withdrawal (COWS scor e ≥5) on any assessment 
will not be eligible for further participation in the trial.  The participant will be released from 
the study center when medically stable, as determined by [CONTACT_093].  Symptoms 
reported in the COWS as a consequence of opi[INVESTIGATOR_591793] a new AE or serious adverse e vent (SAE). 
[IP_ADDRESS].  Instrument Training 
After successful completion of the Naloxone challenge, all eligible participants will undergo 
training on proper completion of the VAS instrument used to col lect the PD endpoints.  This 
will be done to ensure that participants fully understand how to perfor m the test, that they 
feel comfortable with the testing methods used for PD assessmen t and have attained a stable 
level of performance on the various performance-based measures.   Detailed instructions for 
participant training will be provided in a separate st udy specific document. 
[IP_ADDRESS].  Drug Discrimination (Days 1 to 3) 
Following completion of the instrument training, the eligible p articipants will be evaluated for 
drug discrimination.  The purpose of this phase is to select participants who can dis criminate 
between the subjective effects of diazepam 20 mg and placebo wh en administered orally. 
The drug discrimination will be performed over 2 consecutive days.  The treatments will be 
double blind.  The participants w ill be ra ndomly assigned t o receive one of the blinded 
treatments (diazepam 20 mg or placebo) on the first day and the n receive the alternate 
treatment the next day according to a W illiams square design (Table 3). 
Table  3. Schema for Qualification Phase 
Treatment Periods 1 and 2 
Day 1 Day 2 
A B 
B A 
Treatment A: diazepam 20 mg. 
Treatment B: placebo. 
Pharmacodynamic (VAS) and safety assessments (vital signs, puls e oximetry and respi[INVESTIGATOR_862]) will be c onducted at pre-dose and up to [ADDRESS_780371] dosing.  Continuing  eligibility will 
be based on the participant ’s ability to:  
x Assess “Drug Liking ” using the bipolar VAS of 0-100 such that the administration of  
placebo produces a score between 40-60 points;  
x Have a diazepam VAS score outside of the placebo range of at le ast 15 points; 
x Tolerate study treatments safely; ie, SpO 2 ≥90%, no epi[INVESTIGATOR_591794] [ADDRESS_780372]-dose; 
PF-[ADDRESS_780373] dose of either diazepam o r placebo. 
Following completion of Day 2 procedures, the study data for ea ch participant will be 
unblinded and a determination will be made by [CONTACT_23638] i nvestigator (and/or 
designee) if the participant is eligible to continue in the stu dy. 
4.1.3.  Treatment Phase (Visits 3 to 7) 
As shown in the SoA (Table 2), participants who successfully co mplete the Naloxone 
Challenge and the Drug Discrimination Phase and who meet all th e Randomization Criteria 
will be ra ndomized into the Treatment Phase of this randomized, double-bl inded, 
placebo- a nd active-controlled, crossover study. 
On Day [ADDRESS_780374] 14 days, 
participants will r eceive an oral dose of either gabapentin 600 mg, 1200 mg or 1800 mg or 
20 mg dose of diazep am or placebo.  Study treatments w ill be administered under fasted 
conditions (overnight fast and no food until 4 hours after dosing).  Water w ill be allowed 
without restriction un til 1 hour prior to dosing and 1 hour after dosing. 
Physiological and subjective scales will be used to assess the potential for abuse of 3 doses of 
gabapentin compared to single dose of diazepam monotherapy and placebo.  The blood 
samples for the analysis of gabapentin and diazepam (including its major active metabolite: 
N-desmethyldiazepam) in plasma will be obtained pre-dose (immed iately prior to dosing) 
and post-dose as outlined in the SoA (Table 2).  Vital signs in cluding pulse rate (PR), blood 
pressure (BP), respi[INVESTIGATOR_697] (RR), and pulse oximetry w ill be evaluated, and tolerability 
and safety will be assessed for all treatments by [CONTACT_526133] s. 
4.2. Scientific Rationale for Study Design 
There is a need to systematically evaluate the abuse potential of gabapentin with comparison 
to placebo and a positive control (such as diazepam), investiga ting a range of gabapentin 
dose (the highest therapeutic and supra-therapeutic) in a healt hy non-drug dependent 
population with sedative drug abuse experience.  Therefore, the  study design w ill employ a 
10-sequence, 5-period, cross-over design which will include the  placebo, positive control, 
and three doses of gabapentin alone to allow for the various co mparisons to be systematically 
evaluated.  The washout period will be least 14 days minimizing  the carry-over effects of the 
treatments.  PK will be evaluated to allow for an exploratory c orrelation of 
pharmacodynamic effects.  
Banked biospecimens will be collected for exploratory 
pharmacogenomic/genomic/biomarker analyses and retained in the Biospecimen Banking 
System (BBS), which makes it po ssible to better understand the investigational product’s 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 25 mechanism of action and to seek explanations for differences in , for example, exposure, 
tolerability, safety, and/or efficacy not anticipated prior to the beginning of the study. 
4.3. Justification for Dose 
The highest therapeutic single dose of Neurontin® in adults for postherpetic neuralgia is 
600 mg, 3 times a day (TID) (1800 mg/day).  Doses above 1800 mg /day did not demonstrate 
additional clinical benefit.  The recommended maintenance dose of Neurontin® for epi[INVESTIGATOR_591795] 300 mg to 600 mg, TID.  Therefore, three doses of Ne urontin®, 600 mg (highest 
therapeutic single dose), 1200 mg ([ADDRESS_780375] thera peutic single dose), 1800 mg 
([ADDRESS_780376] therapeutic single dose) were selected to adequately explore a rang e of 
doses to determine the abuse potential of Neurontin® when administered orally alone and 
diazepam monotherapy in this study.   
The prescribing dose of diazepam in the management of anxiety d isorders and relief of 
symptoms of anxiety is [ADDRESS_780377] obtained 
significant results with doses of diazepam ranging from 10 to 4 0 mg.  Diazepam showed 
dose-dependent increases in participant- and observer-rated sed ation and drug liking within 
the range (eg, 10 mg, 20 mg, and 40 mg).  A single dose of diaz epam [ADDRESS_780378] acebo group in human abuse 
potential studies.  In the previous [COMPANY_007] human abuse potentia l study (Pregabalin clinical 
study 1008-[ZIP_CODE]), a single dose of diazepam 15 mg or 30 mg in a cross-over des ign was 
given in a moderately heavy sedative/alcohol-using population a nd produced positive 
psychoactive effects indicative of abuse potential.  Thus, a si ngle dose of diazepam 20 mg 
was selected as a positive control for this study. 
Neurontin® formulations are available in capsule, tablet, and oral soluti on.  The marketed 
Diazepam formulations are also available in tablet and oral sol ution.    
4.4. End of Study Definition 
A participant is considered to have completed the study if he/s he has completed all phases of 
the study including the last visit. 
The end of the study is defined as the date of the last visit of the last participant in the study.  
5. STUDY POPULATION 
This study can fulf ill its objectives only if appropriate participants are enrolle d.  The 
following eligibility criteria are designed to select participa nts for whom participation in the 
study is considered appropriate.  All relevant medical and nonm edical cond itions should be 
taken into consideration when deciding whether a participant is suitable for this protocol.  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not perm itted. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 26 5.1. Inclusion Criteria 
Participants are eligible to be included in the study only if a ll the following criteria apply: 
Age and Sex: 
1. Male and female participants must be 18 to 65 years of age, inclusive, at the time of 
screening.  
2. Refer to Appendix 4  for reproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2 ) participants. 
Type of Participant and Disease Characteristics: 
3. Male and female participants who are overtly healthy.  Healthy is defined as no clinically relevant abnorma lities identified by a detailed medical history, complete 
physical examination, vital signs, 12-lead electrocardiogram (ECG), and/or clinical 
laboratory tests.  
4. Participants must be recreational sedative users, defined as th ose reporting using a 
sedative agent (eg, barbiturates, benzodiazepi[INVESTIGATOR_1651]) for its into xicating effects on at 
least [ADDRESS_780379] once in the 12 weeks before the Screening 
Visit (Visit 1), but who have no signs of dependence and are no t seeking treatment for 
their sedative use.  
5. Participants must satisfactorily complete both the Naloxone Cha llenge and the Drug 
Discrimination phases. 
6. Participants who are willing and able to comply with all scheduled visits, treatment 
plan, laboratory tests, lifestyle considerations, and other study procedures. 
Weight: 
7. Body mass index (BMI) of 17.5 to 34 kg/m
2, inclusive; and a total body weight 
>50 kg (110 lb).  
Informed Consent: 
8. Capable of giving signed informed consent as described in Appendix [ADDRESS_780380] ed in the informed 
consent document (ICD) and in this protocol. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 27 5.2. Exclusion Criteria 
Participants are excluded from the study if any of the followin g criteria apply: 
Medical Conditions: 
1. Participants with current or past diagnosis of any type of drug  dependence within 
the past year.  Diagnosis of substance and/or alcohol dependenc e (excluding 
caffeine and nicotine) will be assessed by [CONTACT_591821] (DSM-IV) criteria  performed at 
Screening.  Current drug use will be allowed if the candidate c an produce a 
negative urine sample and are free of any signs/symptoms of wit hdrawal.  The 
candidate will be informed if they have a positive breathalyzer  test.  
2. Participants are heavy smokers or users of other types of nicot ine products (>20 
cigarettes equivalents per day) 
3. Participants are unable to abstain from smoking for at least [ADDRESS_780381] 8 hours after study drug administration.   
4. Evidence or history of clinically significant hematological, re nal, endocrine, 
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatr ic, neurological, or 
allergic disease (including drug allergies, but excluding untre ated, asymptomatic, 
seasonal allergies at the time of dosing). 
5. Participants with any history of sleep apnea, myasthenia or gla ucoma. 
6. Any condition possibly affecting drug absorption (eg, gastrecto my) excluding 
cholecystectomy within 1 year prior to study. 
7. Clinical or laboratory evidence of active hepatitis A infection  or a history of 
human immunodeficiency virus (HIV) infection, hepa titis B, or hepatitis C, and/or 
positive testing for HIV, hepatitis B surf ace antigen (HBsAg), hepa titis B core 
antibody (HBcAb), or hepa titis C anti body (HCVAb).  
8. Participants with active suicidal ideation or suicidal behavior  within 5  year prior 
to Screening as determined through the use of the Columbia-Suic ide Severity 
Rating Scale (C-SSRS) or active ideation identified at Screenin g or on Day -1.  
9. Other acute or chronic medical or psychiatric condition includi ng recent (within 
the past year) or active suicidal ideation or behavior or labor atory abnormality 
that may increase the risk associated with study participation or investigational 
product administration or may interfere with the interpretation  of study results 
and, in the judgment of the investigator, would make the partic ipant inappropriate 
for entry into this study. 
 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 28 Prior/Concomitant Therapy: 
10. Use of prescription or nonprescription drugs and dietary supple ments within 
7 days or 5 half-lives (whichever is longer) prior to the first  dose of 
investigational product.  (Refer to Section 6.5 for additional details). 
11. Herbal supplements and herbal medications must be discontinued at least [ADDRESS_780382] dose of study medication. 
Prior/Concurrent Clinical Study Experience: 
12. Previous administration with an investigational drug within 30 days (or as 
determined by [CONTACT_19970]) or 5 half-lives (whichever  is longer) 
preceding the first dose of investigational product used in thi s study. 
Diagnostic Assessments: 
13. Positive urine drug screen (UDS) for substances of abuse at eac h admission in 
Qualification and Treatment Phase, excluding tetrahydrocannabin ol (THC). If a 
participant presents with a positive UDS excluding THC at any a dmission or any 
visit, the investigator, at his/her discretion, may reschedule a repeat UDS until the 
UDS is negative, excluding THC, before the participant is permi tted to participate 
in any phase of the study.  
14. Participants unable to abstain from using THC during the inpati ent stays in the 
Qualification and Treatment Phases of the study. 
15. Has participated in, is currently participating in, or is seeki ng treatment for 
substance-and/or alcohol-related disorders (excluding nicotine and caffeine). 
16. Has a positive alc ohol breathalyzer test at Screening or upon admission to the 
study center at Visits 2-6.  Pos itive results may be repeated and/or participants 
re-scheduled at the Investigator’s discretions .  
17. Screening sitting BP t140 mm Hg (systolic) or t90 mm Hg (diastolic), following 
at least [ADDRESS_780383].  If BP is t140 mm Hg (systolic) or t90 mm Hg 
(diastolic), the BP should be repeated [ADDRESS_780384] rage of the 3 BP 
values should be used to determine the participant ’s eligibility.   Repeated BP tests 
should be s paced at least 5 minutes apart. 
18. Baseline (screening) 12-lead electrocardiogram (ECG) that demon strates 
clinically relevant abnorma lities that may affect participant safety or 
interpretation of study results (eg, baseline corrected QT (QTc ) interval >450 
msec, complete left bundle branch block [LBBB], signs of an acu te or 
indeterminate-age myocardial infarction, ST-T interval changes suggestive of 
myocardial ischemia, second- or third-degree atrioventricular [ AV] block, or 
serious bradyarrhythmias or tachyarrhythmias).  If the baseline  uncorrected QT 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 29 interval is >450 msec, this interval should be rate-corrected u sing the Fridericia 
method and the resu lting QTcF s hould be used for decision making and reporting.  
If QTc exceed s 450 msec, or QR S exceeds 120 msec, the ECG shoul d be repeated 
2 more times and the average of the 3 QTc or QRS values should be used to 
determine the participant’s eligibility.  Computer -interpreted ECGs should be 
overread by a physician experienced in reading ECGs before excl uding 
participants. 
19. Participants with ANY of the following abnorma lities in clinical laboratory tests 
at screening, as assessed by [CONTACT_1758]-specific laboratory and confirmed by a 
single repeat test, if deemed to be clinically significant in t he opi[INVESTIGATOR_1070]: 
x Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level 
t1.5 × upper limit of normal (ULN); 
x Total bilirubin level t1.5 × ULN; partici pants with a history of Gilbert’ s 
syndrome may have direct b ilirubin measured and would be eligible for this 
study provided the direct b ilirubin level is d ULN. 
Other Exclusions: 
20. Blood donation (excluding plasma donations) of approximately 1 pi[INVESTIGATOR_11731] (500 mL) 
or more within [ADDRESS_780385] of the study.  
5.3. Lifestyle Considerations 
The following guidelines are provided: 
5.3.1.  Meals and Dietary Restrictions 
x Participants must abstain from all food and drink (except water ) at least [ADDRESS_780386] administration.  Water 
may be consumed without restriction beginning 1 hour after dosing.  Noncaffeinated 
drinks (except grapefruit or grapefruit-related citrus fruit ju ices-see below) may be 
consumed with meals and the evening snack. 
x Lunch will be provided approximately 4 hours after dosing. 
x Dinner will be provided approximately 9 to 10 hours after dosing. 
x An evening snack may be permitted. 
x Participants will refrain from consuming red wine, grapefruit, or grapefruit-related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from  [ADDRESS_780387] until collection of the final P K blood sample. 
x While participants are confined, their total daily nutritional composition should be 
approximately 55% carbohydrate, 30% fat, and 15% protein.  The daily caloric intake 
per participant should not exceed approximately 3200 kcal. 
5.3.2.  Caffeine, Alcohol, and Tobacco 
x Participants will abstain from caffeinecontaining products for 24 hours prior to the 
start of dosing until collection of the final PK sample of each study period. 
x Participants will abstain from alcohol for 24 hours prior to admission to the clinical 
research unit (CRU) and continue abstaining from alcohol un til collection of the final 
PK sample of each study period.  Participants may undergo an alcohol breath test or 
blood alcohol test at the discretion of the investigator. 
x Participants will not be permitted to smoke from at least [ADDRESS_780388] 
8 hours after dosing in the Qualification and Treatment Phases.  At all other times 
while housed in the study center, smoking may be perm itted in short breaks at the 
study center staff’s discretion.   The use of oral or chewed tobacco and/or nicotine-
containing products (including topi[INVESTIGATOR_113040]) is not permitte d from at least [ADDRESS_780389] 8 hours after study drug administration.  
5.3.3.  Activity 
x Participants will abstain from strenuous exercise (eg, heavy lifting, weight training, calisthenics, aerobics) for at least 48 hours prior to each blo od collection for clinical 
laboratory tests.  Walking at a normal pace will be permitted. 
5.3.4.  Contraception  
The investigator or his or her designee, in consultation with t he participant, will confirm that 
the participant has selected an appropriate method of contracep tion for the individual 
participant and his or her partner(s) from the permitted list o f contraception methods (see 
Appendix 4 , Section 10.4.4 ) and will confirm that the participant has been instructed in its 
PF-[ADDRESS_780390] use.  At time points indicated in the schedule of activities  (SoA), the 
investigator or designee will inform the participant of the need to use effective contraception 
consistently and correctly and document the conversation and th e part icipant’s affirmation in 
the participant’s chart (participants need to affirm their cons istent and correct use of at least 1 
of the selected methods of contraception).  In addition, the investigator or designee will 
instruct the participant to call immediately if the selected co ntraception method is 
discontinued or if pregnancy is known or suspected in the participant or partner. 
5.4. Screen Failures 
Screen failures are defined as participants who consent to part icipate in the clinical study but 
are not subsequently entered in the Qualification Phase.  Scree n failure data are collected and 
remain as source and are not reported to the clinical database.  
6. STUDY INTERVENTION 
Study intervention is defined as any investigational interventi on(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to 
the study protocol. 
For the purposes of this protocol, the term investigational pro duct m ay be used 
synonymously with study intervention. 
6.1. Study Interventions Administered 
For this study, the investigational products are Neurontin® and diazepam.  
Neurontin® and diazepam w ill be provided by [CONTACT_591822]. 
6.1.1.  Administration 
Following an overnight fast of at least [ADDRESS_780391] at approximately 08:00 hours (±2 hours).  Detailed inst ructions on preparation of all 
study treatments, including steps to maintain the double blind,  will be provided separately in 
Drug Administration Instructions (DAI).  In order to standardize the conditions on PK sampling days, all  participants will be required 
to refrain from lying down (except when required for ECG measur ements), eating, and 
drinking beverages other than water during the first 4 hours after dosing.  Water may only be 
consumed 1 hour following dosing.   
6.2. Preparation/Handling/Storage/Accountability 
1. The investigator or designee must confirm appropriate temperatu re conditions have 
been maintained during transit for all study interventions received and any 
discrepancies are reported and resolved before use of the study  intervention, as 
applicable for temperature-monitored shipments.  
PF-[ADDRESS_780392] be stored in a secure, environmentally contr olled, and monitored 
(manual or automated recording) area in accordance with the lab eled storage 
conditions with access limited to the investigator and authoriz ed site staff.  At a 
minimum, daily minimum and maximum temperatures for all site st orage locations 
must be documented and available upon request.  Data for nonwor king days must 
indicate the minimum and maximum temperature since previously d ocumented for all 
site storage locations upon return to business. 
3. The investigator, institution, or the head of the medical insti tution (where applicable) 
is responsible for study intervention accountab ility, reconciliation, and record 
maintenance (ie, receipt, reconc iliation, and final disposition records).  All st udy 
interventions will be accounted for using an inves tigational prod uct accountab ility 
form/record. 
4. Further guidance and information for the final disposition of u nused study 
interventions are provided in the investigational product (IP) manual. 
5. Any storage conditions stated in the single reference safety do cument (SRSD) will be 
superseded by [CONTACT_591823] l.  
6. Study interventions should be stored in their original containe rs and in accordance 
with the labels.  
7. Deviations from the storage requirements, including any actions  taken, must be 
documented and reported to Sponsor  upon discovery.  The site s hould actively 
pursue options for returning the study intervention to the stor age conditions described 
in the labeling, as soon as possible.  Once an excursion is ide ntified, the study 
intervention must be quarantined and not used until S ponsor  provides permission to 
use the study intervention.  It w ill not be considered a protocol deviation if S ponsor  
approves the use of the study intervention after the temperatur e excursion.  Use of the 
study intervention prior to Sponsor  approval w ill be considered a protocol deviation.  
Specific details regarding the definition of an excursion and i nformation the site 
should report for each excursion w ill be provided to the site in the IP manual. 
8. The sponsor or designee w ill provide guidance on the destruction of unused st udy 
intervention (eg, at the site).  If destruction is authorized t o take place at the 
investigator site, the investigator must ensure that the materi als are destroyed in 
compliance with applicable environmental regulations, instituti onal policy, and any 
special instructions provided by [CONTACT_2728] , and all destruction must be adequately 
documented. 
6.2.1.  Preparation and Dispensing 
Within this protocol, preparation refers to the investigator si te activities performed to make 
the investigational product ready for administration or dispens ing to the participant/caregiver 
PF-[ADDRESS_780393], 
concomitant treatments, and accompanying information by [CONTACT_591824](s) to a 
healthcare provider, participant, or caregiver in accordance wi th this protocol.  Local health 
authority regulations or investigator site guidelines may use a lternative terms for these 
activities. 
Investigational products will be prepared at the CRU in the ind ividual dosing containers by 
[ADDRESS_780394] 1 of whom is an appropriately qualified a nd experienced member of the 
study staff (eg, physician, nurse, physician’s assistant, nurse  practitioner, pharmacy 
assistant/technician, or pharmacist).  The investigational prod ucts will be provided in 
appropriate containers and lab eled in accordan ce with Sponsor  regulations and the clinical 
site’s labeling requirements.   
6.3. Measures to Minimize Bias: Randomization and Blinding 
6.3.1.  Allocation to Investigational Product 
At screening, participants will be assigned a subject screening  identification number 
(SSID)via an automated Interactive Response Technology (IRT)  o r equivalent system. 
Following screening the participants will be ra ndomly assigned a qualification randomization 
number (QRN) via the IRT or equivalent system using a 1:[ADDRESS_780395] udy and w ill correspond to the blinded 
qualification phase. 
 
After satisfactory completion of the qualification phase, participants will ra ndomly be 
assigned a study randomization number (SRN) via the IRT or equivalent system using a 1:[ADDRESS_780396] udy and 
will corres pond to the blinded treatment sequence.  
. 
6.3.2.  Breaking the Blind 
The investigator site, study monitor(s), and Sponsor  personnel  will be blinded to st udy 
treatment.  The site will have an unblinded pharmacist for preparation of the study drugs.  
The unblinded pharmacist or unblinded designee at the study cen ter will be res ponsible for 
ensuring blinding procedure oversight at the study center, according to the study center 
guidelines.  The unblinded pharmacist will not be able to perform any other duties for this 
study outside of the requirements of ensuring the blind.  
At the completion of the Drug Discrimination Phase, the investi gator and/or designee will 
un-blind the subject’s treatment sequence in order for the investigator and Sponsor  pers onnel 
to assess participant eligibility to continue to the Treatment Phase of the study.  Additional 
information regarding the criteria for Drug Discrimination can be found in Section [IP_ADDRESS] .  
Treatment data during the Treatment Phase of the study will rem ain blinded throughout the 
course of treatment until the study database has been locked.  Unblinding during the 
Treatment Phase will not occur unless medically necessary for participant safety. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 34 The IRT will be programmed with blind-breaking instructions.  I n case of an emergency, the 
investigator has the sole responsib ility for determining if unblinding of a participant’s 
treatment assignment is warranted.  Participant safety must alw ays be the first consideration 
in making such a determination.  If the investigator decides th at unblinding is warranted, the 
investigator should make every effort to contact [CONTACT_591825] a participant’s treatment assignment unless this cou ld delay further management 
of the participant.  If a participant’s t reatment assignment is unblinded, the sponsor must be 
notified within [ADDRESS_780397] be recorded in the source documentation and data co llection tool (DCT). 
The study-specific IRT reference manual and IP manual will prov ide the contact [CONTACT_22810].  
6.4. Study Intervention Compliance 
Investigational product will be administered under the supervis ion of investigator site 
personnel.  The oral cavity of each participant w ill be examined following dosing to ensure 
the investigational product was taken. 
6.5. Concomitant Therapy 
Use of prescription or nonprescription drugs and dietary and he rbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of 
investigational product.  Limited use of nonprescription medica tions that are not believed to 
affect participant safety or the overall results of the study m ay be permitted on a case-by-case 
basis following approval by [CONTACT_456] .   
Females using hormonal contraceptives or taking hormone replace ment therapy are eligible 
to participate in this study.  
All concomitant treatments taken during the study must be recor ded with indication, daily 
dose, and start and stop dates of administration.  All particip ants will be questioned about 
concomitant treatment at each clinic visit. 
Treatments taken within [ADDRESS_780398] a fully equipped “crash cart” and advanced cardiac 
life support (ACLS) certified staff present during the entire s tudy. 
x Acute gabapentin and/or diazepam toxicity can be manifested as drowsiness, 
respi[INVESTIGATOR_2341], and somnolence progressing to stupor, c oma or death.  In the 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 35 event that acute gabapentin and/or diazepam toxicity occurs, pr imary attention shall 
be given to re-establishment and/or maintenance of an open airw ay including assisted 
or controlled ventilation.   
x Other supportive measures including the use of oxygen and vasop ressors should be 
employed in the standard management of circulatory shock if it occurs in the event of 
gabapentin and/or diazepam toxicity, or other/further treatment s as appropriate. 
6.8. Intervention After the End of the Study 
No intervention will be provided to study participants at the e nd of the study. 
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL 
7.1. Discontinuation of Study Intervention 
In rare instances, it may be necessary for a participant to per manently discontinue 
investigational product.  If investigational product is permane ntly discontinued, the 
participant will not remain in the study.  See the SoA for data to be collected at the time of 
discontinuation of investigational product. 
ECG Changes  
If the ECG of a participant meets the bulleted criteria below, then 2 more ECGs will be 
performed.  If the average of the three ECGs meets the bulleted criteria below, the participant 
is to be withdrawn from the study.  
x QTc, corrected QT using Bazett’s method ( QTcB), corrected QT using Fridericia’s 
method (QTcF) >500 msec. 
x Change from baseline: QTc >60 msec.  
If a clinically significant finding is identified (including, but not limited to, changes from 
baseline in QTcF after enrollment), the investigator or qualified designee will determine if 
the participant can continue in the study and if any change in participant management is 
needed.  This review of the ECG printed at the time of collecti on must be documented.  Any 
new clinically relevant finding should be reported as an AE. 
See the SoA for data to be collected at the time of intervention discontin uation and follow-up 
and for any further evaluations that need to be completed. 
Potential Cases of Acute Kidney Injury 
Abnormal values in serum creatinine (S Cr) concurrent with presence or absence of increase  
in blood urea nitrogen (BUN) that meet the criteria below, in t he absence of other causes of 
kidney injury, are considered potential cases of acute kidney injury and should be considered 
important medical events.  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 36 An increase of ≥0.3 mg/dL (or ≥26.5 Pmol/L) in SCr level relative to the participant’s own 
baseline measurement should trigger another assessment of SCr a s soon as practically 
feasible, preferably within 48 hours from awareness. 
If the second assessment (after the first observations of ≥0.3 mg/dL [or ≥26.5 Pmol/L] in SCr 
relative to the participant’s  own baseline measurement) is ≥0.4 mg/dL (or ≥35.4 Pmol/L), the 
participant should be discontinued from the study and adequate, immediate, supportive 
measures taken to correct apparent acute kidney injury. 
Participants should return to the investigator site and be evaluated as soon as possible, 
preferably within 48 hours from awareness of the second assessment confirming abnormal 
SCr result.  This evaluation should include laboratory tests, detailed history, and physical 
assessment.  In addition to repeating SCr, laboratory tests sho uld include serum BUN, serum 
creatine kinase, and serum electrolytes (including at a minimum  potassium, sodium, 
phosphate/phosphorus, and calcium), in add ition to urinary dipstick, urine microscopic 
examination, and urinary indices.  All cases confirmed on repea t testing as meeting the 
laboratory criteria for acute kidney injury, with no other caus e(s) of laboratory abnormalities 
identified, should be considered potential cases of drug-induce d kidney injury irrespective of 
availability of all the results of the investigations performed to determine etiology of the abnormal SCr.  If ≥[ADDRESS_780399] 2 consecutive  
SCr results of ≥0.3 mg/dL (or ≥26.5 Pmol/L), an assessment of whether the finding may be 
considered an adverse drug reaction should be undertaken. 
Pregnancy 
In the case of a positive confirmed pregnancy, the participant will be withdrawn from the 
study.  
7.2. Participant Discontinuation/Withdrawal from the Study  
A participant may withdraw from the study at any time at his/he r own request or may be 
withdrawn at any time at the discretion of the investigator for  safety, behavioral, compliance, 
or administrative reasons. 
At the time of discontinuing from the study, if possible, an early discontinuation visit should 
be conducted.  See the SoA for assessments to be collected at the time of study 
discontinuation and follow-up and for any further evaluations that need to be completed.  
The early discontinuation visit applies only to participants wh o are randomized and then are 
prematurely withdrawn from the study.  Participants should be q uestioned regarding their 
reason for withdrawal.  The participant will be permanently dis continued both from the study 
intervention and from the study at that time. 
If a participant withdraws from the study, he/she may request d estruction of any remaining 
samples, but data already generated from the samples will conti nue to be available and may 
be used to protect the integrity of existing analyses.  The inv estigator must document any 
such requests in the site study records. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 37 If the participant withdraws from the study and withdraws conse nt (see below) for disclosure 
of future information, no further evaluations should be perform ed, and no additional data 
should be collected.  The sponsor may retain and continue to us e any data collected before 
such withdrawal of consent. 
When a participant withdraws from the study because of an SAE, the SAE must be recorded 
on the CRF and reported on the Clinical Trial (CT) SAE Report. 
Lack of completion of all or any of the withdrawal/early termin ation procedures will not be 
viewed as protocol deviations so long as the participant ’s safety was preserved.  
Withdrawal of Consent:  
Participants who request to discontinue receipt of study treatm ent will remain in the st udy 
and must continue to be followed for protocol-specified follow- up procedures.  The only 
exception to this is when a participant specifically withdraws consent for any further contact 
[CONTACT_591826].  Participants should notify the investigator in wr iting of the decision to 
withdraw consent from future follow-up, whenever possible.  The  withdrawal of consent 
should be explained in detail in the medical records by [CONTACT_74169], as to whether the 
withdrawal is only from further receipt of investigational prod uct or also from study 
procedures and/or posttreatment study follow-up, and entered on  the appropriate CRF page.  
In the event that vital status (whether the participant is aliv e or dead) is being measured, 
publicly available information should be used to determine vita l status only as appropriately 
directed in accordance with local law. 
7.3. Lost to Follow up  
A participant will be considered lost to follow-up if he or she  repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_539155] e. 
The following actions must be taken if a participant fails to r eturn to the clinic for a required 
study visit: 
x The site must attempt to contact [CONTACT_591827] w ishes to and/or should 
continue in the study; 
x Before a participant is deemed lost to follow-up, the investiga tor or designee must 
make every effort to regain contact [CONTACT_6635] (where  possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’ s last known ma iling 
address or local equivalent methods).  These contact [CONTACT_14386] s hould be documented 
in the participa nt’s medical record ; 
x Should the participant continue to be unreachable, he/she w ill be considered to have 
withdrawn from the study.  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 38 Discontinuation of specific sites or of the study as a whole is  handled as part of Appendix 1 . 
8. STUDY ASSESSMENTS AND PROCEDURES 
Participants will be screened within 28 days prior of the Qualification Phase to confirm that 
they meet the study population criteria for the study.  The inv estigator (or an appropriate 
delegate at the investigator site) must obtain a signed and dat ed ICD before performing any 
study-specific procedures.  If the time between screening and d osing exceeds 28 days as a 
result of unexpected delays (eg, delayed drug shipment), then participants do not require rescreening if the laboratory results obtained prior to first d ose administration meet eligibility 
criteria. 
A participant who qualified for this protocol but did not enrol l from an earlier cohort/group 
may be used in a subsequent cohort/group without rescreening, p rovided laboratory results 
obtained prior to the first dose administration meet eligibility criteria for this study.  In 
addition, other clinical assessments or specimen collections, e g, banked biospecimens, may 
be used without repeat collection, as appropriate.  
Study procedures and their timing are summarized in the SoA.  Protocol waivers or 
exemptions are not allowed. 
Immediate safety concerns should be discussed with the sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue study 
intervention. 
Adherence to the study design requirements, including those spe cified in the SoA, is essential 
and required for study conduct. 
All screening evaluations must be completed and reviewed to con firm that potential 
participants meet all eligibility criteria.  The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable. 
Every effort should be made to ensure that protocol-required te sts and procedures are 
completed as described.  However, it is anticipated that from time to time there may be 
circumstances outside the control of the investigator that may make it unfeasible to perform 
the test.  In these cases, the investigator must take all steps  necessary to ensure the safety and 
well-being of the participant.  When a protocol-required test c annot be performed, the 
investigator will document the reason for the missed test and a ny corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible.  The study team must be informed of these incidents in a timely manner. 
If an IV catheter is utilized for bl ood sample collections, ECGs and vital sign assessments 
(pulse rate and BP) should be collected prior to the insertion of the catheter. 
PF-[ADDRESS_780400] udy. 
The total blood sampling volume for individual participants in this study is approximately 
479 mL.  The actual collection times of blood sampling may chan ge.  Additional blood 
samples may be taken for safety assessments at times specified by [CONTACT_2728], provided the 
total volume taken during the study does not exceed 550 mL during any period of 60 consecutive days. 
To prepare for study participation, participants w ill be instructed on the information in the 
Lifestyle Considerations and Concomitant Therapy sections of th e protocol. 
8.1. Efficacy Asse ssments (Not applicable) 
8.2. Safety Assessments 
Planned time points for all safety assessments are provided in the SoA.  Unscheduled clinical 
laboratory measurements may be obtained at any time during the study to assess any 
perceived safety concerns. 8.2.1.  Physical Examinations 
A complete physical examination w ill include, at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, lymph nodes, and gastrointes tinal, musculoskeletal, and 
neurological systems.  
A brief physical examination w ill include, at a minimum, assessments of general appearance, 
the respi[INVESTIGATOR_110251], and participant-rep orted symptoms.  
Physical examinations may be conducted by a physician, trained physician's assistant, or 
nurse practitioner as acceptable according to local regulation.  
Height and weight will also be measured and recorded as per the  SoA.  For measuring 
weight, a scale with appropriate range and resolution is used a nd must be placed on a stable, 
flat surface.  Participants must remove shoes, bulky layers of clothing, and jackets so that 
only light clothing remains.  They must also remove the content s of their pockets and remain 
still during measurement of weight.  
8.2.2.  Vital Signs 
Sitting BP will be measured with the participant ’s arm supported at the level of the heart , and 
recorded to the nearest mm Hg after approximately [ADDRESS_780401].  The same arm 
(preferably the dominant arm) should be used throughout the stu dy.  Participants should be 
instructed not to speak during measurements. 
The same properly sized and calibrated BP cuff will be used to measure BP each time.  The 
use of an automated device for measuring BP is acceptable.  Pul se rate and oxygen saturation 
will be measured with a pulse oximeter.  When the timing of the se measurements coincides 
PF-[ADDRESS_780402]-drug (See SoA).  These measures are done in abus e liability testing to ensure 
safety. 
Additional collection times, or changes to collection times, of  BP, pulse oximetry and 
respi[INVESTIGATOR_591796], as n ecessary, to ensure appropriate collection of safety 
data. 
If the participant develops orthostatic hypotension, the proced ure for collecting postural or 
orthostatic data will be: 
x Assess BP after the participant is in the supi[INVESTIGATOR_591797] a minimum of 5 minutes; 
x Have the participant stand up for 2 minutes; 
x Assess BP after the participant is in the standing pos ition for approximately 
2 minutes. 
Orthostatic hypotension is defined as a decrease of ≥20 mm Hg for systolic BP or 
≥[ADDRESS_780403] posture from a supi[INVESTIGATOR_591798]: lightheadedness, dizziness, blurred vision, weakness, fatigue, cognitive impairment, 
nausea, palpi[INVESTIGATOR_814], tremulousness, headache, and/or neck ache . 
If a participant has symptoms suggestive of orthostasis, but no t documented orthostatic 
hypotension, repeated measurements of supi[INVESTIGATOR_050]/standing BP should  be obtained.  Lesser 
degrees of BP reduction may still be considered clinically significant if the participant 
becomes symptomatic upon standing, especially in the presence o f a significant increase in 
pulse rate ( ≥30 beats per minute [bpm]). 
[IP_ADDRESS].  Respi[INVESTIGATOR_591799] (RR, breaths/min), pulse oximetry, tidal volum e (VT, mL) and end-tidal 
carbon dioxide (ETCO2, mmHg) will be measured continuously, pre -dose to [ADDRESS_780404]-dose during the Treatment Phase (see SoA). 
[IP_ADDRESS].  Temperature  
Temperature will be measured orally or with a temporal infrared  scanner.  No eating, 
drinking, or smoking is allowed for 15 minutes prior to the ora l measurement. 
8.2.3.  Electrocardiograms 
Twelve (12)-lead ECGs should be collected at times specified in  the SoA section of this 
protocol using an ECG machine that automatically calculates the  heart rate and measures 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 41 pulse rate (PR), QT, and QTc intervals and QRS complex.  All sc heduled ECGs should be 
performed after the participant has rested quietly for at least 10 minutes in a supi[INVESTIGATOR_2547].  
To ensure safety of the participants, a qualified individual at the investigator site will make 
comparisons to baseline measurements.  Additional ECG monitoring will occur if a) a 
post-dose QTc interval is increased by ≥30 msec from the baseline and is >450 msec; or 
b) an absolute QTc value is ≥[ADDRESS_780405]-dose QTc interval remains t30 msec from the baseline and is >450 msec; or b) an 
absolute QTc value is ≥500 msec for any scheduled ECG for greater than 4 hours (or soo ner, 
at the discretion of the investigator), or QTc intervals get pr ogressively longer, the participant 
should undergo continuous ECG monitoring.  A cardiologist should be consulted if QTc 
intervals do not return to less than the criterion listed above  after 8 hours of monitoring (or 
sooner, at the discretion of the investigator).  
In some cases, it may be appropriate to repeat abnormal ECGs to  rule out improper lead 
placement as cont ributing to the ECG abnorma lity.  It is important that leads be placed in the 
same positions each time in order to achieve precise ECG record ings.  If a machine-read QTc 
value is prolonged, as defined above, repeat measurements may n ot be necessary if a 
qualified medical provider ’s interpretation determines that the QTc values are i n the 
acceptable range. 
ECG values of potential clinical concern are listed in Appendix 7. 
[IP_ADDRESS].  Continuous Cardiac Monitoring by [CONTACT_591828] w ill be performed as noted in the SoA. The time, duration, 
and description of any clinically significant abnormal rhythm w ill be reported as an adverse 
event. 8.2.4.  Clinical Safety Laboratory Assessments 
See Appendix [ADDRESS_780406] any 
clinically relevant changes occurring during the study in the A E section of the CRF.  
Clinically significant abnormal laboratory findings are those w hich are not associated with 
the underlying disease, unless judged by [CONTACT_306909]'s condition.  
All laboratory tests with values considered clinically signific antly abnormal during 
participation in the study or within [ADDRESS_780407] dose of study intervention 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 42 should be repeated un til the values return to normal or baseline or are no longer co nsidered 
clinically significant by [CONTACT_10982]. 
If such values do not return to normal/baseline within a period of time judged reasonable by 
[CONTACT_093], the etiology should be identified and the spo nsor notified. 
All protocol-required laboratory assessments, as defined in Appendix 2,  must be conducted 
in accordance with the laboratory manual and the SoA. 
If laboratory values from non-protocol-specified laboratory ass essments performed at the 
institution’s local laboratory require a change in participant management or are considered 
clinically significant by [CONTACT_093] (eg, SAE or AE or do se modification), then the 
results must be recorded in the CRF. 
Participants may undergo random urine drug testing at the discretion of the investigator.  
Drug testing conducted prior to dosing must be negative for par ticipants to receive 
investigational product.  
8.2.5.  Suicidal Ideation and Behavior Risk Monitoring  
[IP_ADDRESS].  Columbia Suicidality Severity Rating Scale (C-SSRS) 
The Columbia Suicide-Severity Rating Scale (C-SSRS) will be col lected at timepoints on the 
SoA.  The C-SSRS is being used in the current study to provide a s ummary measure of 
suicidal ideation and behavior risks.  This scale is to be comp leted by [CONTACT_32341].  Training 
materials on the scale will be provided to investigator sites b y Sponsor . 
[IP_ADDRESS].  Risk Assessment During Sc reening 
The Investigator will review the results of the C-SSRS (baselin e), and medical history.  The 
following criteria would indicate a potential suicide risk: 
x Suicidal ideation associated with actual intent and/or method a nd/or plan and/or 
action (eg, selfharming behaviors) in the past year based on CS SRS assessment 
(“yes” answers on items 4 or 5 of the CSSRS).  
x Any previous history of suicide behaviors reported or documente d within the past 
[ADDRESS_780408] 5 years, an answer of “yes” to any of the 
suicidal behavior items of the CSSRS). 
x Investigator’s judgment.  
If any of these criteria are met and the participant is being considered for study participation, 
a risk assessment must be completed to determine whether it is appropriate for the participant 
to be enrolled. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 43 Risk assessments should be done by a qualified mental health pr ofessional (MHP).  In the 
[LOCATION_002], a qualified MHP is a psychiatrist or a licensed PhD level clinical psychologist.  
In other countries a qualified MHP is a clinically-qualified pr ofessional with appropriate 
training in the assessment of suicide risk (according to the local clinical practice standards and regulations) and who would normally evaluate the risk for s uicide for a participant. 
The MHP may be a member of the study site team.  If an MHP is n ot available within the 
study team, the Investigator should make the necessary referral . 
The Investigator must obtain and review the risk assessment prior to the participant being 
randomized.  A written c opy of the risk assessment should be included in the participan t’s 
clinical record (source documentation). 
[IP_ADDRESS].  Risk Assessment During the Study 
Beginning with Period 1, if there are any “yes” responses on items  4, 5 or on any behavioral 
question of the C-SSRS (since last visit), a risk assessment sh ould be done by a qualified 
MHP to determine whether it is safe for the participant to cont inue to participate in the trial.  
Suicidal risk should be managed appropriately by [CONTACT_591829] a qualified 
MHP (or the Investigator alone if the Investigator is a qualifi ed MHP).  In addition, the 
Investigator should consult with the Sponsor  medical monitor to determine whether the 
participant can continue in the trial. 
A narrative should be prepared for participants who have undergone any post-baseline risk 
assessment, using information from the C-SSRS. 
8.2.6.  Pregnancy Testing  
Pregnancy tests may be urine or serum tests, but must have a se nsitivity of at least 
25 mIU/mL.  Pregnancy tests will be performed in woman of child bearing potential 
(WOCBP) at the times listed in the SoA.  Following a negative pregnancy test result at 
screening, appropriate contraception must be commenced and a se cond negative pregnancy 
test result will be required at the baseline visit prior the participant ’s receiving the study 
treatment.  Pregnancy tests will also be done whenever 1 menstrual cycle is missed during 
the active treatment period (or when potential pregnancy is oth erwise suspected) and at the 
end of the study.  Pregnancy tests may also be repeated if requ ested by [CONTACT_111517] (IRBs)/ethics comm ittees (ECs) or if required by [CONTACT_427].  If a urine test 
cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is 
required.  In such cases, the participant must be excluded if t he serum pregnancy result is 
positive. 
8.3. Adverse Events and Serious Adverse Events 
The definitions of an AE and an SAE can be found in Appendix 3 . 
AEs will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, or 
the participant's legally authorized representative). 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 44 The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome a nd to assess whether it 
meets the criteria for classification as an SAE or that caused the participant to discontinue the 
study (see Section 7 ).  
Each participant will be questioned about the occurrence of AEs  in a nonleading manner. 
In addition, the investigator may be requested by [CONTACT_22835]-up 
information in an expedited fashion. 
8.3.1.  Time Period and Frequency for Collecting AE and SAE Information  
The time period for actively eliciting and collecting AEs and SAEs ( “active collection 
period”) for each participant begins from the time the participant provides infor med consent, 
which is obtained before the participant ’s participation in the study (ie, before undergoi ng 
any study-related procedure and/or receiving investigational pr oduct), through and including 
a minimum of [ADDRESS_780409] SAE Report Form. 
Investigators are not obligated to actively seek AE or SAE afte r conclusion of the study 
participation.  However, if the investigator learns of any SAE,  including a death, at any time 
after a participant has been discharged from the study, and he/ she considers the event to be 
reasonably related to the study intervention, the investigator must promptly report the SAE to 
[COMPANY_007] using the CT SAE Report Form. [IP_ADDRESS].  Reporting SAEs to [COMPANY_007] Safety 
All SAEs occurring in a participant during the active collectio n period as described in 
Section 8.3.[ADDRESS_780410] SAE Repor t Form immediately upon 
awareness and under no circumstance should this exceed 24 hours , as indicated in 
Appendix 3 .  The investigator will submit any updated SAE data to the sponsor within 
24 hours of it being available. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 45 SAEs occurring in a participant after the active collection per iod has ended are reported to 
[COMPANY_007] Safety if the investigator becomes aware of them; at a m inimum, all SAEs that the 
investigator believes have at least a reasonable possibility of  being related to investigational 
product must be reported to [COMPANY_007] Safety. 
[IP_ADDRESS].  Recording Non-serious AEs and SAEs on the CRF 
All nonserious AEs and SAEs occurring in a participant during t he active collection period, 
which begins after obtaining informed consent as described in S ection 8.3.1, will be recorded 
on the AE section of the CRF.  
The investigator is to record on the CRF all directly observed and all spontaneously reported 
AEs and SAEs reported by [CONTACT_2299]. 8.3.2.  Method of Detecting AEs and SAEs 
The method of recording, evaluating, and assessing causa lity of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 . 
Care will be taken not to introduce bias when detecting AEs and /or SAEs.  Open-ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences. 
8.3.3.  Follow-up of AEs and SAEs 
After the initial AE/SAE report, the investigator is required t o proactively follow each 
participant at subsequent visits/contacts.  For each event, the  investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow-up (as defined in Section 7.3 ). 
In general, follow-up information will include a description of  the event in sufficient detail to 
allow for a complete medical assessment of the case and indepen dent determination of 
possible causality.  Any information relevant to the event, such as concomitant medications and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy findings must be submitted as s oon as possible to [COMPANY_007] Safety.  
Further information on follow-up procedures is given in Appendix 3 . 
8.3.4.  Regulatory Reporting Requirements for SAEs 
Prompt notification by [CONTACT_591830] E is essential so that legal 
obligations and ethical responsib ilities towards the safety of participants and the safety of a 
study intervention under clinical investigation are met. 
The sponsor has a legal responsib ility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention un der clinical investigation.  The 
sponsor w ill comply with c ountry-specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRBs/ECs, and investigat ors. 
PF-[ADDRESS_780411] be prepared for suspected unex pected serious adverse 
reactions (S[LOCATION_003]Rs) according to local regulatory requirements a nd sponsor policy and 
forwarded to investigators as necessary. 
An investigator who receives S[LOCATION_003]Rs or other specific safety in formation (eg, summary or 
listing of SAEs) from the sponsor w ill review and then file it along with the SRSD for the 
study and will notify the IRB/EC, if appropriate according to local requirements. 
8.3.5.  Exposure During Pregnancy or Breastfeeding, and Occupational Ex posure 
Exposure to the study intervention under study during pregnancy  or breastfeeding and 
occupational exposure are reportable to [COMPANY_007] Safety within 24 hours of investigator 
awareness. 
[IP_ADDRESS].  Exposure During Pregnancy 
Details of all pregnancies in female participants and, if indic ated, female partners of male 
participants will be collected after the start of study intervention and until [ADDRESS_780412]. 
If a pregnancy is reported, the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy and should follow the procedures outl ined in Appendix 4 . 
An Exposure During Pregnancy (EDP) occurs if:  
x A female participant is found to be pregnant while receiving or  after discontinuing 
study intervention.   
x A male participant who is receiving or has discontinued study i ntervention exposes a 
female partner prior to or around the time of conception.  
x A female is found to be pregnant while being exposed or having been exposed to 
study intervention due to environmental exposure.  Below are ex amples of 
environmental exposure during pregnancy:   
x A female family member or healthcare provider reports that she is pregnant after 
having been exposed to the study intervention or by [CONTACT_591831], eg, ingestion or skin contact. 
x A male family member or healthcare provider who has been exposed to the study 
intervention or by [CONTACT_591832], eg, ingestion or skin contact 
[CONTACT_340758].  
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred.  The in itial information submitted 
should include the anticipated date of delivery (see below for information related to 
termination of pregnancy).  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 47 x If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to [COMPANY_007] Safety on the CT SAE Report Form and  an EDP 
Supplemental Form, regardless of whether an SAE has occurred.  Details of the 
pregnancy will be collected after the start of st udy intervention and un til [ADDRESS_780413] SAE Report Form and E DP Supplemental 
Form.  Since the exposure information does not pertain to the p articipant enrolled in 
the study, the information is not recorded on a CRF; however, a  copy of the 
completed CT SAE Report Form is maintained in the investigator site file. 
Follow-up is conducted to obtain general information on the pre gnancy and its outcome for 
all EDP reports with an unknown outcome.  The investigator will  follow the pregnancy until 
completion (or until pregnancy termination) and notify [COMPANY_007] S afety of the outcome as a 
follow-up to the initial EDP S upplemental Form.  In the case of a live birth, the structural 
integrity of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinicall y possible, the structural 
integrity of the terminated fetus should be assessed by [CONTACT_306915] v isual inspection (unless 
preprocedure test findings are conclusive for a congenital anom aly and the findings are 
reported). 
Abnormal pregnancy outcomes are considered SAEs.  If the outcom e of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abo rtion, intrauterine fetal 
demise, neonatal death, or congenital anomaly [in a live-born b aby, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death]), the investiga tor should follow the procedures 
for reporting SAEs.  Additional information about pregnancy out comes that are reported to 
[COMPANY_007] Safety as SAEs follows:  
x Spontaneous abortion including miscarriage and missed abortion;  
x Neonatal deaths that occur within [ADDRESS_780414] 
to causality, as SAEs.  In addition, infant deaths after 1 mont h should be reported as 
SAEs when the investigator assesses the infant death as related  or possibly related to 
exposure to the study intervention.  
Additional information regarding the EDP may be requested by [CONTACT_3433] e sponsor.  Further 
follow-up of birth outcomes will be handled on a case-by-case b asis (eg, follow-up on 
preterm infants to identify developmental delays).  In the case  of paternal exposure, the 
investigator will provide the participant with the Pregnant Par tner Release of Information 
Form to deliver to his partner.  The investigator must document  in the source documents that 
the participant was given the Pregnant Partner Release of Infor mation Form to provide to his 
partner. 
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal de ath, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 48 [IP_ADDRESS].  Exposure During Breastfeeding 
Scenarios of exposure during breastfeeding must be reported, ir respective of the presence of 
an associated SAE, to [COMPANY_007] Safety within 24 hours of the inve stigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is  not created wh en a [COMPANY_007] 
drug specifically approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences  an SAE associated with such 
a drug’s administration, the SAE is reported together with t he exposure during breastfeeding. 
An exposure during breastfeeding occurs if: 
x A female participant is found to be breastfeeding while receivi ng or after 
discontinuing study intervention. 
x A female is found to be breastfeeding while being exposed or ha ving been exposed to 
study intervention (ie, environmental exposure).  An example of  environmental 
exposure during breastfeeding is a female family member or heal thcare provider who 
reports that she is breastfeeding after having been exposed to the study intervention 
by [CONTACT_22837].   
The investigator must report exposure during breastfeeding to P fizer Safety within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred.  The 
information must be reported using the CT SAE Report Form.  Whe n exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the study , so the information is not recorded on a 
CRF.  However, a c opy of the completed CT SAE Report Form is maintained in the 
investigator site file. 
An exposure during breastfeeding report is not created when a P fizer drug specifically 
approved for use in breastfeeding women (eg, vitamins) is admin istered in accord with 
authorized use.  However, if the infant experiences an SAE asso ciated with such a drug, the 
SAE is reported together with the exposure during breastfeeding . 
[IP_ADDRESS].  Occupational Exposure 
An occupational exposure occurs when a person receives unplanne d direct contact [CONTACT_22839], which may or may not lead to the occurrence  of an AE.  Such persons 
may include healthcare providers, family members, and other rol es that are involved in the 
trial p articipant’s care.  
The investigator must report occupational exposure to [COMPANY_007] Sa fety within 24 hours of the 
investigator’s awareness regardless of whether there is  an associated SAE.  The information 
must be reported using the CT SAE Report Form.  Since the infor mation does not pertain to a 
participant enrolled in the study, the information is not recor ded on a CRF; however, a copy 
of the completed CT SAE Report Form is maintained in the invest igator site file. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 49 8.3.6.  Cardiovascular and Death Events 
Not applicable 
8.3.7.  Disease-Related Events and/or Disease-Related Outcomes Not Qual ifying as AEs 
or SAEs 
Not applicable 
8.3.8.  Adverse Events of Special Interest 
Not applicable 
[IP_ADDRESS].  Lack of Efficacy 
Not applicable since this is an abuse liability st udy in healthy participants. 
8.3.9.  Medical Device Deficiencies 
Not applicable 
8.3.10.  Medication Errors 
Medication errors may result from the administration or consump tion of the investigational 
product by [CONTACT_19995], or at the wrong time, or at t he wrong dosage strength.    
Exposures to the investigational product under study may occur in clinical trial settings, such 
as medication errors. 
Safety Event Recorded on the CRF Reported on the CT SAE Report Form to [COMPANY_007] Safety Within 
24
 Hours of Awareness 
Medication errors  All (regardless of whether associated with an AE) Only if associated with an SAE 
Medication errors include: 
x Medication errors involving participant exposure to the investi gational product; 
x Potential medication errors or uses outside of what is foreseen  in the protocol that do 
or do not involve the study participant. 
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE pa ge. 
In the event of a medication dosing error, the sponsor should b e notified immediately. 
Whether or not the medication error is accompanied by [CONTACT_1149], as  determined by [CONTACT_1275], the medication error is recorded on the medicatio n error page of the CRF and, if 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 50 applicable, any associated AE(s), serious and non-serious, are recorded on an AE page of the 
CRF. 
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_780415] SAE Report 
Form only when associated with an SAE.  
8.4. Treatment of Overdose 
For this study, any dose of Neurontin® >1800 mg or diazepam >20 mg within a 24-hour time 
period will be considered an overdose. 
Sponsor does not recommend specific treatment for an overdose. 
In the event of an overdose, the investigator should: 
1. Contact [CONTACT_10990]. 
2. Closely monitor the participant for any AEs/SAEs and laboratory  abnormalities until 
gabapentin and diazepam can no longer be detected systemically (at least 3 days). 
3. Obtain a blood sample for PK analysis within [ADDRESS_780416] dose of 
study intervention if requested by [CONTACT_7195] (determi ned on a case-by-case 
basis). 
4. Document the quantity of the excess dose as well as the duration of the overdose in 
the CRF. 
5. Overdose is reportable to Safety only when associated with an SAE.  
Decisions regarding dose interruptions or modifications will be  made by [CONTACT_78256]. 
8.5. Pharmacokinetics  
Blood samples of approximately 5 mL, to provide a total of approximately 2 mL of plasma 
volume, will be collected for measurement of plasma concentrati ons of gabapentin and 
diazepam as specified in the SoA.  Instructions for the collection and handling of biological 
samples will be provided in the laboratory manual or by [CONTACT_97280].  The actual date and 
time (24-hour clock tim e) of each sample w ill be recorded. 
The actual times may change, but the number of samples will remain the same.  All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing.  Collection of 
samples up to and including 10 hours after dose administration that are obtained within 5 
minutes or 10% of the nominal time (eg, within 6 minutes of a 6 0-minute sample), whichever 
is greater, relative to dosing will not be captured as a protocol deviation, as long as the exact 
time of the collection is noted on the source document and data  collection tool (eg, CRF).  
Collection of samples more than 10 hours after dose administrat ion that are obtained ≤[ADDRESS_780417] time of the collection is noted on the source  document and data collection 
tool (eg, CRF).  
Samples will be used to evaluate the PK of gabapentin and diaze pam (including its major 
active metabolite, N-desmethyldiazepam).  Samples collected for analyses of gabapentin and 
diazepam plasma concentration may also be used to evaluate safety or efficacy aspects 
related to concerns arising during or after the study, for meta bolite identification and/or 
evaluation of the bioanalytical method, or for other internal exploratory purposes. 
Genetic analyses will not be performed on these plasma samples.  Participant confidentiality 
will be maintained. 
The PK samples must be processed and shipped as indicated in th e instructions provided to 
the investigator site to maintain sample integrity.  Any deviat ions from the PK sample 
handling procedure (eg, sample collection and processing steps,  interim storage or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented and reported to the sponsor.  
On a case-by-case basis, the sponsor may make a determination a s to whether sample 
integrity has been compromised. 
Drug concentration information that may unblind the study w ill not be reported to 
investigator sites or blinded personnel until the st udy has been unblinded. 
Any changes in the timing or addition of time points for any planned study assessments must 
be documented and approved by [CONTACT_372011], but w ill not constitute a protocol amendment.  The IRB/EC w ill 
be informed of any safety issues that require alteration of the  safety monitoring scheme or 
amendment of the ICD. 
8.6. Pharmacodynamics 
8.6.1.  Subjective Effects 
The questionnaire described below is used in drug abuse as well  as clinical efficacy and 
toxicity evaluation of pharmacologic agents, and its usefulness  is widely accepted.  
Furthermore, previous results indicate that the instrument is s ensitive, reliable, and valid. 
8.6.2.  Visual Analog Scale (VAS)  
The VAS consists of horizontal 100-mm lines, each labeled with an adjective such as “Drug 
Liking” or “High”, etc.   Participants will be instructed to pl ace a mark on each line indicating 
how they feel at the moment.  For example, measuring “Drug Liking” on the bipolar VAS, 
the participant will be asked: Do you like the drug effect you are feeling now?  The 
participant will then rate on the 0 to 100 scale, where: Strong disliking = 0; Neither like or 
Dislike = 50; and Strong Liking = 100.  Further information on follow-up procedures is given 
in Appendices 10  and 11. All VAS testing will be administered at the nominal time points 
±[ADDRESS_780418]-dose, w ithin ±[ADDRESS_780419]-dose, and within ±[ADDRESS_780420]-dose.  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 52 Primary Endpoints: 
x VAS for Drug Liking presented on a bipolar 0 to 100 scale. 
Secondary Endpoints: 
x VAS for High presented on a unipolar 0 to 100 scale. 
x VAS for Take Drug Again presented on a bipolar 0 to 100 scale. 
x VAS for Overall Drug Liking presented on a bipolar 0 to 100 sca le. 
x VAS for Any Drug Effects, Good Effects, and Bad Effects presented on unipolar 0 to 
100 scales. 
Additional Secondary Endpoint: 
x Modified Observer's Assessment of Alertness/Sedation scale or comparable scale. 
8.7. Genetics  
8.7.1.  Specified Genetics 
Specified genetics are not evaluated in this study. 
8.7.2.  Banked Biospecimens for Genetics 
A 4-mL blood sample optimized for deoxyribonucleic acid (DNA) i solation Prep D1 will be 
collected as local regulations and IRBs/ECs allow.  
Banked biospecimens may be used for research related to drug response.  Genes and other 
analytes (eg, proteins, ribonucleic acid (RNA), nondrug metabol ites) may be studied using 
the banked samples.  
Unless prohibited by [CONTACT_168086]/EC decision, part icipants will be asked to 
indicate on the consent document whether they will allow their banked biospecimens to also 
be used to design and conduct research in order to gain a further understanding of other 
diseases and to advance science, including development of other  medicines for patients.  This 
component of the sampling banking is optional for participants;  they may still participate in 
the study even if they do not agree to the add itional research on their banked biospecimens.  
The optional additional research does not require the collection of any further samples.  
See Appendix 5  for information regarding genetic research.  Details on proces ses for 
collection and shipment of these samples can be found in the La b Manual. 
8.8. Biomarkers 
Biomarkers are not evaluated in this study. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 53 8.9. Health Economics 
Health economics/medical resource u tilization and health economics parameters are not 
evaluated in this study. 
9. STATISTICAL CONSIDERATIONS  
Detailed methodology for summary and statistical analyses of th e data collected in this study 
is outlined here and further detailed in a statistical analysis  plan (SAP), which will be 
maintained by [CONTACT_456].  The SAP may modify what is ou tlined in the protocol where 
appropriate; however, any major modifications of the primary en dpoint definitions or their 
analyses will also be reflected in a protocol amendment. 
Statistically, the study w ill be evaluated as a safety st udy.  Consequently, the null hypothesis 
for gabapentin will be constructed on the presumption that thes e treatments produce abuse 
potential similar to placebo.  To demonstrate that these treatm ents have no abuse potential 
the null hypothesis w ill be statistically rejected. 
The SAP will be developed and finalized before database lock an d will describe the 
participant populations to be included in the analyses, and pro cedures for accounting for 
missing, unused, and spurious data.   
9.1. Statistical Hypotheses 
To assess the abuse potential of gabapentin the following tests will be performed in the order 
they are given: 
Study Validation: 
The sensitivity and integrity of the st udy w ill be validated by [CONTACT_591833], the pos itive control (C), to the pl acebo (P):  
H0: μC - μP ≤ δ1 versus H a: μC - μP > δ1 where δ1 =15. 
Gabapentin versus diazepam: 
1. Does gabapentin (T) produce mean responses that show less abuse  potential than 
diazepam? 
H0: μC - μT ≤ δ2 versus H a: μC - μT > δ2 where δ2 =0. 
Gabapentin versus placebo (Primary): 
2. Does gabapentin (T) produce mean responses that show abuse pote ntial similar to 
placebo? 
H0: μT - μP ≥ δ3 versus H a: μT - μP < δ3 where δ3 =11. 
PF-[ADDRESS_780421] will be assessed 
for all doses of gabapentin. 
9.2. Sample Size Determination 
An 11-point VAS E max “Drug Liking” difference between the treatment and the p lacebo is 
being selected as the cutoff for demonstrating abuse.  This criterion is clinically meaningful 
for oral drug discrimination and is within the range used by [CONTACT_591834].17-20  This assumes no difference in Bipolar VAS for “ Drug Liking ” 
Emax for the comparison of gabapentin to placebo and a standard dev iation of [ADDRESS_780422] 90% power for the 
comparison of gabapentin to placebo at the 1-sided significance  level of 0.05.  This study 
will ra ndomize approximately [ADDRESS_780423] 20% will be females to ensure that the findings are valid 
across different populations. 
9.3. Populations for Analysis  
The following populations are planned for this study: 
x The Safety Population w ill include all participants who r eceive at least one dose of 
study drug, beginning with the Naloxone Challenge.  This popula tion will be 
analyzed as treated. 
x The PK population w ill include all enrolled participants treated who have at least  
[ADDRESS_780424]-dose re sponse on the VAS for 
Drug Liking within 2 hours of T max for each treatment group: ie , at least one VAS 
response within the interval 0-3h postdose (assuming the Tmax o f 20 mg diazepam is 
1h) and at least one VAS response within the interval 1-5h postdose (assuming the 
Tmax of 600/1200/1800 mg gabapentin is 3h).  This population will be analyzed as 
randomized. 
x The Modified Completer Population w ill include all randomized participants in the 
Completer Population, but w ill exclude any participant who meet either or both of the 
following criteria for Drug Liking VAS: 
1. Emax scores are within a 5 point difference across all five tre atments (ie, 
Maximum Emax score – Minimum Emax score ≤5);  
2. Emax(P) > 60 AND Emax(P) - Emax(Dia) ≥5;  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 55 where Emax(P) and Emax(Dia) are the VAS Emax scores for placebo  and diazepam 
[ADDRESS_780425] the PD conclusions of the 
study.  Prior to unblinding the Treatment Phase data, the spons or (or designee) will 
identify protocol violations or adverse events that would disqu alify a participant from 
the evaluable population and determine which participants or pa rticipant visits will be 
excluded.  This population w ill be analyzed as randomized. 
All PD analyses will be performed using the Modified Completer Population and all 
available post-dose data; these will be the primary PD analyses .  Key PD analyses may be 
repeated on the Evaluable Population using all available post-d ose data. 
9.4. Statistical Analyses 
The SAP will be developed and finalized before database lock an d will describe the 
participant populations to be included in the analyses, and pro cedures for accounting for 
missing, unused, and spurious data.  This section is a summary of the planned statistical 
analyses of the primary and secondary endpoints. 
9.5. Interim Analyses 
No formal interim analysis will be c onducted for this study. 
9.6. Endpoint Analysis 
The following parameters will be calculated for VAS for “Drug Liking”  (primary endpoint)  
and VAS for “High” (secondary endpoint) during the Treatment Period: 
x Maximum (peak) effect (E max); calculated as maximum change from pre-dose 
response if pre-dose assessment is performed; the neutral VAS p oint (50 for Drug 
liking, 0 for High) will be used as pre-dose response when VAS not performed or 
missing. 
x Time of maximum (peak) effect (TE max); 
x Area under the effect curve to the last measurement (AUEC last); 
x Area under the effect curve to 1 hour (AUEC 1); 
x Area under the effect curve to 2 hours (AUEC 2); 
PF-[ADDRESS_780426] curve to 3 hours (AUEC 3); 
x Area under the effect curve to 4 hours (AUEC 4); 
x Area under the effect curve to 8 hours (AUEC 8). 
The additional endpoints of VAS for “Overall Drug Liking ”, “Take Drug Again ”, “Good 
Drug Effect” , “Bad Drug Effect” , and “Any Drug Effect” and the observer -rated assessment 
of alertness/sedation will be summarized by [CONTACT_591835]. 
9.7. Study Validity Analysis of Endpoints 
Study validity w ill first be confirmed through the comparison of mean E max for Drug Liking 
between diazepam [ADDRESS_780427].  If the treatment 
comparison of diazepam 20 mg vs. placebo is statistically signi ficant by a margin of 
15 (ie, one-sided p ≤0.05) in the appropriate direction, it will confirm the sensiti vity of the 
study.  If study validity is not confirmed, comparisons between  gabapentin and diazepam will 
not be performed. 
9.8. Analysis of Primary and Secondary Endpoints 
A linear mixed-effects model that includes site, period, sequen ce, and treatment as fixed 
effects, and the participant as a random effect w ill be used.  The primary analyses of abuse 
potential will be based on testing the differences between the means from the primary 
measure(s) at the peak of drug response effects (VAS E max) produced by [CONTACT_313157], 
diazepam and placebo at a significance level of 0.05 (1-sided).  
The primary PD endpoint is the Emax of bipolar VAS for “ Drug Liking ”.  
The principal parameters for the primary and secondary endpoint s will be summarized by 
[CONTACT_53846] (mean, standard deviatio n [SD], median, first and third 
quartiles, minimum and maximum).  These parameters will be anal yzed using a mixed -effect 
model with treatment, period, and sequence as fixed effects, an d participant nested within the 
sequence as a random effect.  Analyses of endpoints with baseli ne (pre-dose) measurements 
will include the baseline measurement as a covariate in the mod el.  Least squares means, 
standard errors, and 90% confidence intervals will be provided for each treatment and for the 
difference between treatments.  Data will be summarized graphic ally, where appropriate. 
The treatment comparison to test for study validity will be: 
x diazepam 20 mg vs. placebo; (This comparison is used for valida tion of the study and 
adjustments for multiple comparisons will not be applied for th is treatment 
comparison).  
Comparisons of gabapentin versus diazepam will be: 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 57 x gabapentin 600 mg vs.  diazepam 20 mg;  
x gabapentin 1200 mg v s. diazepam 20 mg; 
x gabapentin 1800 mg vs.  diazepam 20 mg.  
Comparisons of gabapentin versus placebo will be (Primary): 
x gabapentin 600 mg  vs. placebo;  
x gabapentin 1200 mg  vs. placebo;  
x gabapentin 1800 mg vs. placebo. 
Statistical significance of all treatment differences will be r eported.  All statistical tests will 
be conducted using one tailed significance criteria.  These com parisons will be used to assess 
the primary study objective.  
Regression diagnostics will be performed to verify model assump tions and adequacy of the 
fitted linear models for the primary endpoints.  Levene’s test wi ll be used to diagnose 
potential heterogeneity of variance and the Shapi[INVESTIGATOR_2152] –Wilk test will be used to diagnose 
potential non-normality of the model residuals. 
If the resulting p-value from Leven e’s test is ≤0.05, the null hypothesis of equal variances is 
rejected and it will be concluded that there is a difference be tween the treatment group 
variances.  An unequal variance model will then be applied usin g the Satterthwaite method in 
order to produce an accurate F-approximation. 
If the resulting p-value from the Shapi[INVESTIGATOR_2152]- Wilk test is ≤0.05, symmetry of the distribution of 
paired differences will be tested using the Triples Test and ei ther the t-test (symmetry) or 
sign test (asymmetry) will be performed. 
9.8.1.  Pharmacodynamic Analysis 
PD parameter values that will be evaluated are listed in Table 4.  The pre-dose psychometric 
measurements of each period w ill be the baseline for calculating the changes in these 
parameters post dose.  Descriptive statistics for the changes f rom baseline will be reported by 
[CONTACT_591836].  The changes from baseline wil l be analyzed with an 
analysis of variance (ANOVA) model consisting of: Site, Sequenc e, Site*Sequence, Period, 
Treatment, Time, Period*Time, Site*Treatment and Treatment*Time  terms as fixed effects, 
and a participant (Site*Sequence) term as a random effect for t esting Site, Sequence, and 
Site*sequence effect. Site*Treatment interaction will be evalua ted and this interaction term 
will be dropped from the final model if it is not significant. To accommodate the repeated 
measures aspect of the design, a compound symmetric covariance matrix will be employed, 
with the participant set to Period*Participant (Sequence).  The  Treatment*Time least-squares 
means and differences among them will be assessed for trends li kely to be of clinical 
relevance. 
PF-[ADDRESS_780428] quartile (Q1), median, third quartile (Q3) and m aximum for each subjective 
measure, each treatment and each paired difference among treatm ents will be calculated and 
used to create tables and graphs. 
As an exploratory analysis, the time course of the different su bjective measures in relation to 
each other (and to abuse-related AEs) w ill evaluate the outcome of positive or negative 
assessments of the drug before, during and after the peak of dr ug effects.  The physiological 
effects such as pulse rate, blood pressure and respi[INVESTIGATOR_591800] e administered and the PK of 
the drug. 
9.8.2.  Derivation of Pharmacodynamic Parameters  
PD parameters for VAS “Drug Liking” and “High” will be derived from the concentration-
time profiles as shown in Table [ADDRESS_780429] (E last) Lin ea r t ra pezo idal m etho d 
AUEC [ADDRESS_780430] operating procedures.  If deem ed necessary, samples of 
placebo and diazepam (including its major active metabolite; N- desmethyldiazepam) will be 
analyzed.  This will be done to primarily confirm that plasma levels of the drug are 
equivalent between participants and to evaluate whether subject ive measures and AEs can be 
correlated with drug levels over time.  Typi[INVESTIGATOR_897], blood will b e drawn immediately after the 
collection of subjective measures are completed at each time po int.  If an analysis shows that 
a participant had low plasma levels of a drug, it may account f or a lack of subjective 
responses in a drug session.  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 59 [IP_ADDRESS].  Pharmacokinetic Parameters 
The PK parameter values for gabapentin and, if deemed necessary , for diazepam (including 
its major active metabolite as data permit: N-desmethyldiazepam ) will be calculated for each 
non-placebo treatment  and each participant using noncompartment al analysis of 
concentration-time data.  PK parameter values that will be eval uated are listed in Table 5. 
The PK parameters (AUC inf, AUC last, Cmax, tmax, t½, partial AUCs [AUC 1, AUC 2, AUC 3, 
AUC 4, AUC 8]) will be derived for each participant/period/analyte and w ill be summarized by 
[CONTACT_591837].  Individual participant PK parameters, a s well as summary statistics 
(eg, group averages, SD, geometric means, coefficient of variat ion [CV], and geometric 
CV%) by [CONTACT_591838], as approp riate.  Plasma 
concentration-time profiles of gabapentin, diazepam and its met abolite 
(N-desmethyldiazepam) will be presented.  Concentrations will b e listed and summarized by 
[CONTACT_591839]. 
[IP_ADDRESS].  Derivation of Pharmacokinetic Parameters  
PK parameters will be derived from the concentration-time profi les as shown in Table 5. 
Table  5. Derivation of Pharmacokinetic Parameters 
Parameter Definition Method of Determination 
Cmax Maximum plasma concentr ation Observed directly from data 
Tmax Tim e f o r C max Observed directly from data as 
time of first occurrence  
AUC last Area under the plasma concentration-time profile from 
time [ADDRESS_780431] quantifiable concentration 
(Clast) Linea r/Log tra pezoidal method 
AUC infa Area under the plasma concentration-time profile from 
t im e [ADDRESS_780432] + (C last*/k el), 
where  Clast* is the predicted  
plasma  concentration at the  last 
quantifiable  t ime  point 
estimated  f rom t he lo g- linear  
regression  a naly sis 
AUC 1 Area under the plasma concentration-time profile from 
time 0 to 1 hour postdose  Linea r/Log tra pezoidal method 
AUC 2 Area under the plasma concentration-time profile from 
time 0  to 2 hour postdose Linea r/Log tra pezoidal method 
AUC 3 Area under the plasma concentration-time profile from 
time 0  to 3 hour postdose Linea r/Log tra pezoidal method 
AUC 4 Area under the plasma concentration-time profile from 
time 0  to 4 hour postdose Linea r/Log tra pezoidal method 
AUC 8 Area under the plasma concentration-time profile from 
time 0  to 8 hour postdose Linea r/Log tra pezoidal method 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 60 Table  5. Derivation of Pharmacokinetic Parameters 
Parameter Definition Method of Determination 
t½a  Terminal elimination half-life  Log e(2)/k el, 
where  kel is the terminal phase 
rate constant  calculated by  a 
linea r  regressio n  o f  t he lo g-
linea r  concentration-time curve.  
Only  those data points judged 
to describe the  terminal log -
linea r  decline will be used in the  
regression  
a. If data permit. 
9.9. Efficacy Analyses 
An efficacy analysis is not a pplicable  to this study.  
9.10. Safety Analyses 
All safety analyses will be performed on the safety population.  
The safety data will be described and summarized in accordance with the sponsor’s Data 
Standards. 
AEs, ECGs, BP, RR, PR, SpO2, continuous cardiac monitoring, and  safety laboratory data 
will be reviewed and summarized on an ongoing basis during the study to evaluate the safety 
of participants.  Any clinical laboratory, ECG, BP, and pulse r ate abnorma lities of potential 
clinical concern will be described.  Safety data will be presen ted in tabular and/or graphical 
format and summarized descriptively, where appropriate. 
Medical history and physical examination and neurological exami nation information, as 
applicable, collected during the course of the study w ill be considered source data and will 
not be required to be reported, unless otherwise noted.  Howeve r, any untoward findings 
identified on physical and/or neurological examinations conduct ed during the active 
collection period will be captured as AEs, if those findings me et the definition of an AE.  
Data collected at screening that are used for inclusion/exclusi on criteria, such as laboratory 
data, ECGs, and vital signs, will be considered source data, an d will not be required to be 
reported, unless otherwise noted.  Demographic data collected a t screening will be reported. 
9.10.1.  Electrocardiogram Analyses 
Electrocardiogram results collected at Screening will be listed . 
9.11. Exploratory Analyses 
Exploratory analysis will be c onducted to evaluate the correlation between drug (gabapentin 
or diazepam) concentrations  and selected P D endpoints ( Bipolar VAS for “Drug Liking” and 
Unipolar VAS for “High”), as data permit.  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 61 9.12. Data Monitoring Committee  
This study w ill not use a data monitoring committee (DMC). 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 62 10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS 
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerat ions 
10.1.1.  Regulatory and Ethical Considerations 
This study w ill be c onducted in accordance with the protoco l and with the following : 
x Consensus ethical principles derived from international guideli nes including the 
Declaration of Helsinki and Council for International Organizat ions of Medical 
Sciences (CIOMS) International Ethical Guidelines; 
x Applicable International Council for Harmonisation (ICH) Good C linical Practice 
(GCP) guidelines; 
x Applicable laws and regulations, including applicable privacy l aws. 
The protocol, protocol amendments, ICD, USPIs, and other releva nt documents 
(eg, advertisements) must be reviewed and approved by [CONTACT_591840]/EC by [CONTACT_22843] /EC before the study is 
initiated. 
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to s tudy participants. 
The investigator will be res ponsible for the following: 
x Providing written summaries of the status of the study to the I RB/EC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/EC; 
x Notifying the IRB/EC of SAEs or other significant safety findin gs as required by 
[CONTACT_1744]/EC procedures; 
x Providing oversight of the conduct of the study at the site and  adherence to 
requirements of 21 Code of Federal Regulations (CFR), ICH guide lines, the IRB/EC, 
European regulation 536/2014 for clinical studies (if applicabl e), and all other 
applicable local regulations. 
[IP_ADDRESS].  Reporting of Safety Issues and Serious Breaches of the Protocol  or ICH GCP 
In the event of any prohibition or restriction imposed (ie, cli nical hold) by [CONTACT_22844], or if the invest igator is aware of any new 
information that might influence the evaluation of the benefits  and risks of the investigational 
product, Sponsor  should be informed immediately.  
PF-[ADDRESS_780433] s during the course of the study 
and for 1 year after completion of the study. 
10.1.3.  Informed Consent Process 
The investigator or his/her representative will explain the nat ure of the study to the 
participant or his/her legally authorized representative and an swer all questions regarding the 
study. 
Participants must be informed that their participation is volun tary.  Participants or their 
legally authorized representative will be required to sign a st atement of informed consent that 
meets the requirements of [ADDRESS_780434] (HIPAA) requirements, where applicable, and the IRB/EC 
or study center. 
The investigator must ensure that each study participant or his  or her legally authorized 
representative is fully informed about the nature and objective s of the study, the sharing of 
data related to the study, and possible risks associated with p articipation, including the risks 
associated with the processing of the participant ’s personal data.  
The participant must be informed that his/her personal study-re lated data will be used by [CONTACT_20004].  The leve l of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records m ay be examined by [CONTACT_591841] t he sponsor, by 
[CONTACT_6667]/EC members, and by [CONTACT_306920] a uthorities. 
The investigator further must ensure that each study participan t or his or her legally 
authorized representative is fully informed about his or her ri ght to access and correct his or 
her personal data and to withdraw consent for the processing of  his or her personal data. 
The medical record must include a statement that written inform ed consent was obtained 
before the participant was enrolled in the study and the date t he written consent was obtained.  
The authorized person obtaining the informed consent must also sign the IC D. 
Participants must be reconsented to the most current version of  the ICD(s) during their 
participation in the study. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 64 A copy of the ICD (s) must be provided to the participant or the participant’s le gally 
authorized representative. 
A participant who is rescreened is not required to sign another  ICD if the rescreening occurs 
within 28 days from the previous ICD signature [CONTACT_568]. 
10.1.4.  Data Protection 
All parties will comply with all applicable laws, including law s regarding the implementation 
of organizational and technical measures to ensure protection o f participant data. 
Participants’ personal data will be stored at the st udy site in encrypted electronic form and 
will be pa ssword protected to ensure that only authorized study staff hav e access.  T he study 
site will implement appropriate technical and organizational me asures to ensure that the 
personal data can be recovered in the event of disaster.  In th e event of a potential personal 
data breach, the study site shall be responsible for determinin g whether a personal data 
breach has in fact occurred and, if so, providing breach notifi cations as required by [CONTACT_2371]. 
To protect the rights and freedoms of natural persons with rega rd to the processing of 
personal data, participants will be assigned a single, particip ant-specific numerical code.  
Any participant records or data sets that are transferred to th e sponsor will contain the 
numerical code; participant names will not be transferred.  All  other identifiable data 
transferred to the sponsor w ill be identified by [CONTACT_20007], participant-specific code.  T he 
study site w ill maintain a confidential list of participants who participat ed in the study, 
linking each participant ’s numerical code to his  or her actual identity.  In case of data 
transfer, the sponsor w ill protect the confidentiality of participant s’ personal data consistent 
with the clinical study agreement and applicable privacy laws. 
10.1.5.  Dissemination of Clinical Study Data 
Viatris fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.go v), the European Clinical Trials 
Database (EudraCT), and other public registries in accordance w ith applicable local 
laws/regulations.  In addition, Viatris reports study results o utside of the requirements of 
local laws/regulations pursuant to its standard operating proce dures (SOPs). 
In all cases, study results are reported by [CONTACT_591842], accurate, balanced, and 
complete manner and are reported regardless of the outcome of t he study or the country in 
which the study was conducted. 
 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 65 www.clinicaltrials.gov 
Viatris posts clinical trial US Basic Results on www.clinicaltr ials.gov for Viatris-sponsored 
interventional studies (conducted in patients) that evaluate th e safety and/or efficacy of a 
product, regardless of the geographical location in which the s tudy is conducted.  US Basic 
Results are generally submitted for posting within 1 year of th e primary completion date  
(PCD) for studies in adult populations or within [ADDRESS_780435] 
Viatris posts European Union (EU) Basic Results on EudraCT for all Viatris-sponsored 
interventional studies that are in scope of EU requirements.  E U Basic Results are submitted 
for posting within 1 year of the PCD for studies in adult popul ations or within 6 months of 
the PCD for studies in pediatric populations. 
Documents within marketing authorization packages/submissions 
Viatris complies with the European Union Policy 0070, the proac tive publication of clinical 
data to the European Medicines Agency (EMA) website.  Clinical data, under Phase 1 of this 
policy, includes clinical overviews, clinical summaries, CSRs, and appendices containing the 
protocol and protocol amendments, sample CRFs, and statistical methods.  Clinical data, 
under Phase 2 of this policy, includes the publishing of indivi dual participant data.  Policy 
0070 applies to new marketing authorization applications submit ted via the centralized 
procedure since 01 January 2015 and applications for line exten sions and for new indications 
submitted via the centralized procedure since 01 July 2015.   
Data Sharing 
Viatris provides researchers secure access to patient-level dat a or full CSRs for the purposes 
of “bona -fide scientific research” that contribute to the scientific und erstanding of the 
disease, target, or compound class.  Viatris w ill make available data from these trials 
[ADDRESS_780436] include a b iostatistician.  Data will not 
be provided to applicants with significant conflicts of interes t, including individuals 
requesting access for commercial/compe titive or legal purposes. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 66 10.1.6.  Data Quality Assurance 
All participant data relating to the study w ill be recorded on printed or electronic CRF unless 
transmitted to the s ponsor or designee electronically (eg, laboratory data).  The i nvestigator is 
responsible for verifying that da ta entries are accurate and co rrect by [CONTACT_18027]. 
The investigator must maintain accurate documentation (source d ata) that supports the 
information entered in the CRF. 
The investigator must ensure that the CRFs are securely stored at the study site in encrypted 
electronic form and are password protected to prevent a ccess by [CONTACT_20011]. 
The investigator must permit study-related monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to sour ce data documents.  This 
verification may also occur after study completion.  It is impo rtant that the investigator(s) 
and their relevant personnel are available during the monitorin g visits and possible audits or 
inspections and that sufficient time is devoted to the process.  
Monitoring details describing strategy (eg, risk-based initiati ves in operations and quality 
such as risk management and mitigation strategies and analytica l risk-based monitoring), 
methods, responsib ilities, and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on-site monitoring),  are provided in the 
monitoring plan. 
The sponsor or designee is responsible for the data management of this study, including 
quality checking of the data. 
Study monitors w ill perform ongoing source data verification to confirm that da ta entered 
into the CRF by [CONTACT_1191], complet e, and verifiable from source 
documents; that the safety and rights of participants are being  protected; and that the study is 
being conducte d in accordance with the currently approved proto col and any other study 
agreements, ICH GCP, and all applicable regulatory requirements . 
Records and documents, including signed ICDs, pertaining to the  conduct of this study must 
be retained by [CONTACT_1732] [ADDRESS_780437] ensure that the records continue to be stored  securely for as long as they are 
maintained. 
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_306891]. 
The investigator(s) will notify the s ponsor or its agents immediately of any regulatory 
inspection notification in relation to the study.  Furthermore,  the investigator will c ooperate 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 67 with the sponsor or its agents to prepare the investigator site  for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present duri ng the inspection.  The 
investigator site and investigator will promptly resolve any di screpancies that are identified 
between the study data and the participant's medical records.  The investigator will promptly 
provide copi[INVESTIGATOR_306892].  Before response 
submission to the regulatory authorities, the investigator will  provide the sponsor or its 
agents with an opportunity to review and comment on responses t o any such findings. 
10.1.7.  Source Documents 
Source documents provide evidence for the existence of the part icipant and substantiate the 
integrity of the data collected.  Source documents are filed at  the investigator site. 
Data reported on the CRF or entered in the electronic CRF (eCRF ) that are transcribed from 
source documents must be consistent with the source documents o r the discrepancies must be 
explained.  The investigator may need to request previous medic al records or transfer 
records, depending on the study.  Also, current medical records  must be available. 
Definition of what constitutes source data can be found in the Clinical Monitoring Plan. 
10.1.8.  Study and Site Closure 
The sponsor designee reserves the right to close the study site  or terminate the study at any 
time for any reason at the sole discretion of the sponsor.  Stu dy sites will be closed upon 
study completion.  A study site is considered closed when all r equired documents and study 
supplies have been collected and a study-site closure visit has  been performed. 
The investigator may initiate study-site closure at any time up on notification to the sponsor if 
requested to do so by [CONTACT_22846]/EC or if such termina tion is required to protect the 
health of study participants. 
Reasons for the early closure of a study site by [CONTACT_306923] y include but are not limited 
to: 
x Failure of the investigator to comply with the protocol, the re quirements of the 
IRB/EC or local health author ities, the s ponsor's procedures, or GCP guidelines; 
x Inadequate recruitment of participants by [CONTACT_093]; 
x Discontinuation of further study intervention development. 
Study termination is also provided for in the clinical study ag reement.  If there is any conflict 
between the contract and this protocol, the contract will contr ol as to termination rights. 
10.1.9.  Publication Policy 
The results of this study may be published or presented at scie ntific meetings by [CONTACT_22847] 1 year after end of the study (or 
study termination), whichever comes first.  
PF-[ADDRESS_780438] e ditorial and ethical practice, the 
sponsor w ill support publication of mu lticenter studies only in their entirety and not as 
individual site data.  In this case, a coordinating investigato r will be designated by 
[INVESTIGATOR_73261]. 
Authorship of publications for the overall study results w ill be determined by [CONTACT_591843].  
If publication is addressed in the clinical study agreement, th e publication policy set out in 
this section will not apply. 
10.1.10.  Sponsor’s Qualifi ed Medical Personnel 
The contact [CONTACT_1133]'s appropriately qualifi ed medical personnel for the 
study is documented in the  study contact [CONTACT_505858].  
To facilitate access to appropriately qualified medical personnel on study-re lated medical 
questions or problems, participants are provided with a contact  [CONTACT_1137].  The contact [CONTACT_95504], at a minimum, protocol and investigational product id entifiers, participant numbers, 
contact [CONTACT_22850], and contact [CONTACT_591844] a contact [CONTACT_591845] a medical 
question or problem originating from another healthcare profess ional not involved in the 
participant ’s participati on in the study.  The contact [CONTACT_591846]; however, it should be used 
only in the event that the established communication pathways b etween the investigator site 
and the study team are not available.  It is therefore intended  to augment, but not replace, the 
established communication pathways between the investigator sit e and the study team for 
advice on medical questions or problems that may arise during t he study.   
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 69 10.2. Appendix 2: Clinical Laboratory Tests 
The following safety laboratory tests (Table 6) will be perform ed at times defined in the SoA 
section of this protocol.  Additional laboratory results may be  reported on these samples as a 
result of the method of analysis or the type of analyzer used b y the clinical laboratory; or as 
derived from calculated values.  These additional tests would n ot require additional 
collection of blood.  Unscheduled clinical laboratory measureme nts may be obtained at any 
time during the study to assess any perceived safety concerns. 
Table 6. Protocol-Required Safety Laboratory Tests 
Hematology Chemistry Urinalysis Other 
Hemoglobin 
Hematocrit  
RBC count  
MCV  
MCH  
MCHC  
Platelet count  
WBC count  
Total neutrophils (Abs) 
Eosinophils (Abs)  
Monocytes (Abs)  
Basophils (Abs)  
Lymphocytes (Abs) BUN/urea and 
creatinine  
Glucose (fasting)  
Ca lcium  
Sodium  
Potassium  
Chloride  
Total CO 2 (bica rbonate) 
AST, ALT  
Tota l bilirubin  
Alkaline phosphatase 
Uric acid  
Albumin  
Total protein pH 
Glucose (qual)  
Protein (qual)  
Blood (qual)  
Ketones  
Nitrites  
Leukocyte esterase 
Urobilinogen  
Urine bilirubin  
Microscopya FSHb 
Urine drug screeningc 
Alcohol breatha lyzer 
β-hCGd 
Hepatitis B s urface 
Antigen 
Hepatitis B core 
Antibody  
Hepatitis C core 
Antibody 
Human 
Immunodeficiency 
Virus 
 Additional Tests 
(Need ed  f o r H y’s La w)   HAV IgM 
HAV IgG 
 AST, ALT (repeat) 
Tota l bilirubin (repeat) 
Albumin (repeat)  
Alkaline phosphatase 
(repeat)  
Direct bilirubin  
Indirect bilirubin  
CK 
GGT  
PT/INR  
Tota l bile a cids  
Aceta minophen drug 
a nd/or protein adduct 
levels   
Abbrevia tions: ALT = a la nine a minotransferase; AST = a spartate aminotransferase; β-hCG = b et a h uman 
chorionic gonadotropin; BUN = blood urea nitrogen; FSH = fo llicle stimulating hormone; GGT = ga mma 
gluta myl tra nsferase; HAV IgG = hepa titis A virus immunoglobuli n G; HAV IgM = hepatitis A virus 
immunoglobulin M; INR = international normalized ratio; MCH = m ean corpuscular hemoglobin; MCHC 
= mean corpuscular hemoglobin concentr ation; MCV = mean corpusc ular volume; PT = prothrombin 
time; RBC = red blod cell; W BC = white blood cell.  
 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 70 Table 6. Protocol-Required Safety Laboratory Tests 
Hematology Chemistry Urinalysis Other 
a. Only if urine dipstick is positive for bl ood, protein, nitrites or leukocyte esterase. 
b. For confirmation of postmenopausal status only. 
c. The minimum requirement for drug screening includes cocaine, tetrahydrocannabinol (THC), opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], 
benzodiazepi[INVESTIGATOR_1651], and amphetamines (others are site and st udy specific). 
d. Serum or urine E-hCG for female participants of childbearing potential.  
 
Investigators must document their review of each laboratory saf ety report. 
Laboratory/analyte results that could unblind the study will no t be reported to investigator 
sites or other blinded personnel until the st udy has been unblinded. 
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administra tion may be retained and 
stored for the duration of the study.  Upon completion of the s tudy, these retained safety 
samples may be used for the assessment of exploratory safety bi omarkers or unexpected 
safety findings.  These data will not be included in the CSR.  Samples to be used for this 
purpose will be shipped to either a Viatris-approved Biospecime n Banking System (BBS) 
facility or other designated laboratory and retained for up to 1 year following the completion 
of the study. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 71 10.3. Appendix 3: Adverse Events: Definitions and Procedures for Reco rding, 
Evaluating, Follow-up, and Reporting 
10.3.1.  Definition of AE 
AE Definition 
x An AE is any untoward medical occurrence in a patient or clinic al study 
participant, temporally associated with the use of study interv ention, whether or 
not considered related to the study intervention. 
x NOTE: An AE can therefore be any unfavorable and uni ntended sign (including 
an abnormal laboratory finding), symptom, or disease (new or ex acerbated) 
temporally associated with the use of study intervention. 
Events Meeting the AE Definition 
x Any abnormal laboratory test results (hematology, clinical chem istry, or 
urinalysis) or other safety assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, consi dered clinically 
significant in the medical and scientific judgment of the inves tigator.  Any 
abnormal laboratory test results that meet any of the cond itions below must be 
recorded as an AE: 
x Is associated with accompanying symptoms; 
x Requires additional diagnostic testing or medical/surgical inte rvention; 
x Leads to a change in study dosing (outside of any protocol- specified dose 
adjustments) or discontinuation from the study, significant add itional 
concomitant drug treatment, or other therapy. 
x Exacerbation of a chronic or interm ittent preexisting c ondition including either 
an increase in frequency and/or intensity of the condition. 
x New conditions detected or diagnosed after study intervention a dministration 
even though it may have been present before the start of the st udy. 
x Signs, symptoms, or the clinical sequelae of a suspected drug-d rug intera ction. 
x Signs, symptoms, or the clinical sequelae of a suspected overdo se of either study 
intervention or a concomitant medication.  Overdose per se will not be reported 
as an AE/SAE unless it is an intentional overdose taken with po ssible 
suicidal/self-harming intent.  Such overdoses should be r eported regardless of 
sequelae. 
 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 72 Events NOT Meeting the AE Definition 
x Any clinically significant abnormal laboratory findings or othe r abnormal safety 
assessments which are associated with the underlying disease, unless judged by 
[CONTACT_591847]’s condition.  
x The disease/disorder being studied or expected progression, sig ns, or symptoms 
of the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.  
x Medical or surgical procedure (eg, endoscopy, appendectomy): th e condition that 
leads to the procedure is the AE. 
x Situations in which an untoward medical occurrence did not occu r (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]). 
x Anticipated day-to-day fluctuations of preexisting disease(s) o r condition(s) 
present or detected at the start of the study that do not worse n. 
10.3.2.  Definition of SAE 
If an event is not an AE per definition above, then it cannot b e an SA E even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of t he disease under study, death 
due to progression of disease). 
An SAE is defined as any untoward medical occurrence that, at a ny dose: 
a. Results in death 
b. Is life-threatening 
The term “life-threatening ” in the definition of “serious ” refers to an event in which the 
participant was at risk of death at the time of the event.  It does not refer to an event that 
hypothetically might have caused death if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_9234], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_446953]/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting.  Complications that occur during hospi[INVESTIGATOR_1084].  If a  
complication prolongs hospi[INVESTIGATOR_446954], the event is 
serious.   When in doubt as to whether “hospi[INVESTIGATOR_059]”  occurred or was necessary, the 
AE should be considered serious.  
Hospi[INVESTIGATOR_5187] a preexisting conditi on that did not worsen from 
baseline is not considered an AE.  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 73 d. Results in persistent disability/incapacity 
x The term disability m eans a substantial disruption of a person’s ability to c onduct 
normal life functions. 
x This definition is not intended to include experiences of relat ively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may interfere with  or 
prevent everyday life functions but do not constitute a substan tial disruption.  
e. Is a congenital anomaly/birth defect 
f. Other situations: 
x Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediately life- threatening or result in death or hospi[INVESTIGATOR_591801] n.  These events 
should usually be considered serious. 
x Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059] , or development of 
drug dependency or drug abuse.  
10.3.3.  Recording/Reporting and Follow-up of AEs and/or SAEs 
AE and SAE Recording/Reporting 
The table below summarizes the requirements for recording adver se events on the CRF 
and for reporting serious adverse events on the Clinical Trial (CT) Serious Adverse 
Event (SAE) Report Form to [COMPANY_007] Safety.  These requirements a re delineated for 
3 types of events: (1) SAEs; (2) nonserious adverse events (AEs); and (3) exposure to 
the investigational product under study during pregnancy or bre astfeeding, and 
occupational exposure.  
It should be noted that the CT SAE Report Form for reporting of  SAE information is not 
the same as the AE page of the CRF.  When the same data are col lected, the forms must 
be completed in a consistent manner.  AEs should be recorded us ing concise medical 
terminology and the same AE term should be used on both the CRF  and the CT SAE 
Repor t Form for reporting of SAE information. 
PF-[ADDRESS_780439] 
under study during 
pregnancy or 
breastfeeding, and 
occupational exposure None All (and exposure during 
pregnancy [ EDP] 
supplemental form for 
EDP)   
x When an AE/SAE occurs, it is the responsib ility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostic 
reports) related to the event. 
x The investigator will then record all relevant AE/SAE informati on in the CRF. 
x It is not acceptable for the investigator to send photocopi[INVESTIGATOR_113759]’s 
medical records to [COMPANY_007] Safety in lieu of completion of the CT SAE Report 
Form/AE/SAE CRF page. 
x There may be instances when copi[INVESTIGATOR_306895].  In this case, all participant iden tifiers, with the 
exception of the partic ipant number, will be redacted on the copi[INVESTIGATOR_19953]. 
x The investigator will attempt to establish a diagnosis of the e vent based on signs, 
symptoms, and/or other clinical information.  Whenever possible , the diagnosis 
(not the individual signs/symptoms) will be documented as the A E/SAE. 
Assessment of Intensity 
The investigator will make an assessment of intensity for each AE and SAE reported 
during the study and assign it to 1 of the following categories :  
x Mild: An event that is easily tolerated by [CONTACT_2299], cau sing minimal 
discomfort and not interfering with everyday activities. 
x Moderate: An event that causes sufficient discomfort and interf eres with normal 
everyday activities. 
x Severe: An event that prevents normal everyday activities.  An AE that is 
assessed as severe should not be confused with an SAE.  Severe is a category 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 75 utilized for rating the intensity of an event; and both AEs and  SAEs can be 
assessed as severe. 
x An event is defined as “serious ” when it meets at least 1 of the predefined 
outcomes as described in the definition of an SAE, NOT when it is rated as 
severe. 
 
Assessment of Causality 
x The investigator is obligated to assess the relationship betwee n study intervention 
and each occurrence of each AE/SAE. 
x A “reasonable possibility” of a relationship conveys that there  are facts, 
evidence, and/or arguments to suggest a causal relationship, ra ther than a 
relationship cannot be ruled out. 
x The investigator will use clinical judgment to determine the re lationship. 
x Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event  to study intervention 
administration will be considered and investigated. 
x The investigator will also consult the i nvestigator’s brochure (IB) and/or p roduct 
information, for marketed products, in his/her assessment. 
x For each AE/SAE, the investigator must  document in the medical notes that 
he/she has reviewed the AE/SAE and has provide d an assessment of causality. 
x There may be situations in which an SAE has occurred and the in vestigator has 
minimal information to include in the initial report to the spo nsor.  However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data  to the 
sponsor. 
x The investigator may change his/her opi[INVESTIGATOR_35816]- up 
information and send an SAE follow-up report with the updated c ausality 
assessment. 
x The causality assessment is one of the criteria used when deter mining regulatory 
reporting requirements. 
x If the investigator does not know whether or not the investigat ional product 
caused the event, then the event will be handled as “related t o investigational 
product” for reporting purposes, as defined by [CONTACT_456] .  In addition, if the 
investigator determines that an SAE is associated with study pr ocedures, the 
PF-[ADDRESS_780440] of 
supplemental measurements and/or evaluations as medically indic ated or as 
requested by [CONTACT_22854]/or causality of the AE or 
SAE as fully as possible.  This may include additional laborato ry tests or 
investigations, histopathological examinations, or consultation  with other 
healthcare providers. 
x If a participant dies during participation in the study or duri ng a recognized 
followup period, the investigator wil l provide [COMPANY_007] Safety with a copy of any 
postmortem findings including histopathology.   
x New or updated information w ill be recorded in the originally completed CRF. 
x The investigator will submit any updated SAE data to the sponsor within 
24 hours of receipt of the information. 
10.3.4.  Reporting of SAEs 
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collectio n Tool 
x The primary mechanism for reporting an SAE to [COMPANY_007] Safety wil l be the 
electronic data collection tool. 
x If the electronic system is unavailable, then the site will use  the paper SAE data 
collection tool (see next section) in order to report the event  within 24 hours.  
x The site will enter the SAE data into the electronic system as soon as the data  
become available. 
x After the study is completed at a given site, the electronic da ta collection tool 
will be taken off- line to prevent the entry of new data or changes to existing da ta. 
x If a site receives a report of a n ew SAE from a study participa nt or receives 
updated data on a previously reported SAE after the electronic data collection 
tool has been taken off- line, then the site can report this information on a paper 
SAE form (see next section) or to [COMPANY_007] Safety by [CONTACT_756]. 
 
PF-[ADDRESS_780441] SAE Report Form pages within the desig nated 
reporting time frames. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 78 10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information 
10.4.1.  Male Participant Reproductive Inclusion Criteria 
Male participants are eligible to participate if they agree to the following requirements during 
the intervention period and for at least [ADDRESS_780442]  dose of study intervention, which 
corresponds to the time needed to eliminate study intervention( s) plus an additional 90 days 
(a spermatogenesis cycle):  
x Refrain from donating sperm. 
PLUS either : 
x Be abstinent from heterosexual intercourse as their preferred a nd usual lifestyle 
(abstinent on a long-term and persistent basis) and agree to re main abstinent;  
OR 
x Must agree to use contraception/barrier as detailed below:  
x Agree to use a male condom when engaging in any activity that a llows for passage of 
ejaculate to another person. 
x Male participants should be advised of the benefit for a female  partner to use a highly 
effective method of contraception, as a condom may break or lea k when having 
sexual intercourse with a WOCBP who is not currently pregnant. 
10.4.2.  Female Participant Reproductive Inclusion Criteria 
A female participant is eligible to participate if she is not p regnant or breastfeeding, and at 
least 1 of the following conditions applies: 
x Is not a WOCBP (see definitions below in Section 10.4.3 ); 
OR 
x Is a WOCBP and using a contraceptive method, as described below , during the 
intervention period and for at least [ADDRESS_780443] dos e of study intervention, 
which corresponds to the time needed to eliminate any study int ervention(s).   
x A WOCBP agrees not to donate eggs (ova, oocytes) for the purpose of reproduction 
during this period. The investigator should evaluate the effectiveness of the 
contraceptive method in relationship to the first dose of study  intervention. 
The investigator is responsible for review of medical history, menstrual history, and recent 
sexual activity to decrease the risk for inclusion of a woman with an early undetected 
pregnancy.  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 79 10.4.3.  Woman of Childbearing Potential (WOCBP) 
A woman is considered fertile following menarche and until beco ming postmenopausal 
unless permanently sterile (see below). 
If fertility is unclear (eg, amenorrhea in adolescents or athle tes) and a menstrual cycle cannot 
be confirmed before the first dose of study intervention, addit ional evaluation should be 
considered. 
Women in the following categories are not considered WOCBP: 
1. Premenopausal female with 1 of the following: 
x Documented hysterectomy; 
x Documented bilateral salpi[INVESTIGATOR_1656]; 
x Documented bilateral oophorectomy. 
For individuals with permanent infertility due to an alternate medical cause other 
than the above, (eg, mullerian agenesis, androgen insens itivity), investigator 
discretion should be applied to determining study entry. 
Note: Documentation for any of the above categories can come fr om the site 
personnel’s review of the participant’s medical records, medica l examination, or 
medical history interview.  The method of documentation should be recorded in 
the participant’s medical record for the study.  
2. Postmenopausal female. 
x A postmenopausal state is defined as age 60 years or older or n o menses for 
12 months without an alternative medical cause.  
x A high follicle-stimulating hormone (FSH) level in the postmeno pausal range 
may be used to confirm a postmenopausal state in women not usin g hormonal 
contraception or hormone replacement therapy (HRT).  
x Females on HRT and whose menopausal status is in doubt w ill be required to use 
at least one of the contraception methods below. 
10.4.4.  Contraception Methods 
Female subjects of child-bearing potential must use at least on e form of the following 
contraception methods. 
1. Intrauterine device (IUD).  
2. Bilateral tubal occlusion. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 80 3. Hormonal contraception. 
4. Contraceptive implants. 
5. Double-barrier method (any combination of physical and chemical  methods). 
6. Confirmed infertility of sexual partner. 
7. Engaged exclusively in a same-sex relationship. 
8. Total abstinence (periodic abstinence is not acceptable). 
9. Vasectomized partner. 
x Vasectomized partner is a highly effective contraceptive method  provided that the 
partner is the sole sexual partner of the woman of childbearing  potential and the 
absence of sperm has been confirmed.  If not, an additional met hod of 
contraception should be used.  The spermatogenesis cycle is app roximately 
90 days. 
 
Collection of Pregnancy Information 
For both unapproved/unlicensed products and for marketed produc ts, an exposure during 
pregnancy (EDP) occurs if: 
x A female becomes, or is found to be, pregnant either while rece iving or having been 
exposed (eg, because o f treatment or environmental exposure) to  the investigational 
product; or the female becomes or is found to be pregnant after  discontinuing and/or 
being exposed to the investigational product; 
x An example of environmental exposure would be a case involving direct contact [CONTACT_4490] 
a [COMPANY_007] product in a pregnant woman (eg, a nurse reports that she is pregnant and has 
been exposed to chemotherapeutic products); 
x A male has been exposed (eg, because of treatment or environmen tal exposure) to the 
investigational product prior to or around the time of concepti on and/or is exposed 
during his partner’s pregnancy.  
If a participant or participant ’s partner becomes or is  found to be pregnant during the 
participant ’s treatment with the investigational product, the investigator  must report this 
information to [COMPANY_007] Safety on the CT SAE Report Form and an E DP supplemental form, 
regardless of whether an SAE has occurred.  In addition, the in vestigator must submit 
information regarding environmental exposure to a [COMPANY_007] produc t in a pregnant woman (eg, a 
participant reports that she is pregnant and has been exposed t o a cytotoxic product by 
[CONTACT_4691][INVESTIGATOR_4598]) to [COMPANY_007] Safety using the EDP s upplemental form.  This must be done 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 81 irrespective of whether an AE has occurred and within 24 hours of awareness of the 
exposure.  The information subm itted should include the anticipated date of delivery (see 
below for information related to termination of pregnancy). 
Follow-up is conducted to obtain general information on the pre gnancy and its outcome for 
all EDP reports with an unknown outcome.  The investigator will  follow the pregnancy until 
completion (or until pregnancy termination) and notify [COMPANY_007] S afety of the outcome as a 
follow-up to the initial EDP s upplemental form.  In the case of a live birth, the structural 
integrity of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinicall y possible, the structural 
integrity of the terminated fetus should be assessed by [CONTACT_306915] v isual inspection (unless 
preprocedure test findings are conclusive for a congenital anom aly and the findings are 
reported). 
If the outcome of the pregnancy meets the criteria for an SAE ( ie, ectopic pregnancy, 
spontaneous abortion, intrauterine fetal demise, neonatal death , or congenital anomaly [in a 
live-born baby, a terminated fetus, an intrauterine fetal demis e, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs. 
Additional information about pregnancy outcomes that are report ed to [COMPANY_007] Safety as SAEs 
follows:  
x Spontaneous abortion includes miscarriage and missed abortion; 
x Neonatal deaths that occur within [ADDRESS_780444].  
Additional information regarding the EDP may be requested by [CONTACT_3433] e sponsor.  Further 
follow-up of birth outcomes will be handled on a case-by-case b asis (eg, follow-up on 
preterm infants to identify developmental delays).  In the case  of paternal exposure, the 
investigator will provide the participant with the Pregnant Par tner Release of Information 
Form to deliver to his partner.  The investigator must document  in the source documents that 
the participant was given the Pregnant Partner Release of Infor mation Form to provide to his 
partner. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 82 10.5. Appendix 5: Genetics 
Use/Analysis of DNA 
x Genetic variation may impact a participant’s response to study interven tion, 
susceptibility to, and severity and progression of disease.  Th erefore, where local 
regulations and IRBs/ECs allow, a bl ood sample w ill be collected for DNA analysis. 
x Genetic research may consist of the analysis of 1 or more candi date genes or the 
analysis of genetic markers throughout the genome (as appropria te). 
x The samples may be analyzed as part of a multist udy assessment of genetic factors 
involved in the response to gabapentin and diazepam or study in terventions of this 
class to understand treatments for the disease(s) under study o r the disease(s) 
themselves. 
x The results of genetic analyses may be reported in the clinical  study report (CSR) or 
in a separate study summary, or may be used for internal decision making without 
being included in a study report. 
x The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.  
x The samples will be retained as indicated: 
x Samples for banking (see Section 8.7.2 ) will be stored indefinitely or other period as 
per local requirements.   
x Participants may withdraw their consent for the storage and/or use of their banked 
biospecimens at any time by [CONTACT_7328] a request to the investigato r; in this case, any 
remaining material will be destroyed.  Data already generated from the samples will be retained to protect the integrity of existing analyses.   
x Banked biospecimens will be labeled with a code.  The key betwe en the code and the 
participant’s personally identifying information (eg, name, address) will be held at the 
study site and w ill not be provided to the sample bank. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 83 10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Asses sments 
Potential Cases of Drug-Induced Liver Injury 
Humans exposed to a drug who show no sign of liver injury (as d etermined by [CONTACT_20023]) are termed “tolerators,” while those who show tr ansient liver injury, but adapt 
are termed “adaptors.”  In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome.  These participants fail to ada pt and therefore are 
"susceptible" to progressive and serious liver injury, commonly  referred to as drug-induced 
liver injury (DILI).  Participants who experience a transaminas e elevation above 3 times the 
upper limit of normal ( × ULN) should be monitored more frequently to determine if they are 
an “adaptor” or are “susceptible.”  
Liver function tests (LFTs) results should be managed and follo wed as described below. 
In the majority of DILI cases, elevations in AST and/or ALT pre cede total bilirubin (TBili) 
elevations (>2 × ULN) by [CONTACT_22857].  The increase in TBili typi[INVESTIGATOR_1306] y occurs 
while AST/ALT is/are still elevated a bove 3 × ULN (ie, AST/ALT and TBili values will be 
elevated within the same laboratory sample).  In rare instances , by [CONTACT_20024], AST/ALT values might have decreased.  This occurr ence is still regarded as a 
potential DILI.  Therefore, abnormal elevations in either AST O R ALT in addition to TBili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law 
criteria) cases and should always be considered important medic al events, even before all 
other possible causes of liver injury have been excluded. 
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underlying conditions.  Participants who present 
with the following laboratory abnormalities s hould be evaluated further as potential DILI 
(Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:  
x Participants with AST/ALT and TBili  baseline values within the normal range who 
subsequently present with AST OR ALT values >3 × ULN AND a TBili value 
>2 × ULN with no evidence of hemolysis and an alkaline phosphat ase value 
<2 × ULN or not available. 
x For participants with baseline AST OR ALT OR TBili values above the ULN, the 
following threshold values are used in the definition mentioned  above, as needed, 
depending on which values are above the ULN at baseline: 
x Preexisting AST or ALT baseline values above the normal range:  AST or ALT values 
>2 times the baseline values AND >3 × ULN; or >8 × ULN (whichever is smaller). 
x Preexisting values of TBili above the normal range: TBili level  increased from 
baseline value by [CONTACT_8895] 1 × ULN or if the value reaches >3 × ULN 
(whichever is smaller). 
PF-[ADDRESS_780445]/ALT and TBili separated by [CONTACT_726] a few weeks s hould be assessed 
individually based on clinical judgment; any case where uncerta inty remains as to whether it 
represents a potential Hy’s law case should be reviewed with th e sponsor.   
The participant should return to the investigator site and be e valuated as soon as possible, 
preferably within [ADDRESS_780446] and ALT and TBili for suspected cases of 
Hy’s law, additional laboratory tests should include albumin, creati ne kinase (CK), direct and 
indirect bilirubin, gamma-glutamyl transferase (GGT), prothromb in time (PT)/international 
normalized ratio (INR), total bile acids, and alkaline phosphat ase.  Consideration should also 
be given to drawing a separate tube of clotted blood and an ant icoagulated tube of blood for 
further testing, as needed, for further contemporaneous analyse s at the time of the recognized 
initial a bnorma lities to determine etiology.  A detailed history, including re levant 
information, such as review of ethanol, acetaminophen (either b y itself or as a coformulated 
product in prescription or over-the-counter medications), recre ational drug, supplement 
(herbal) use and consumption, family history, sexual history, t ravel history, history of contact 
[CONTACT_4490] a jaundiced person, surgery, blood transfusion, history of  liver or allergic disease, and 
potential occupational exposure to chemicals, should be collect ed.  Further testing for acute 
hepatitis A, B, C, D, and E infection and liver imaging (eg, bi liary tract) and collection of 
serum sample for acetaminophen drug and/or protein adduct level s may be warranted.  
All cases demonstrated on repeat testing as meeting the laborat ory criteria of AST/ALT and 
TBili elevation defined above should be considered potential DI LI (Hy’s law) cases if no 
other reason for the liver function test (LFT) abnorma lities has yet been found.  Such 
potential DILI (Hy’s law) cases are to be reported as SAEs, irr espective of availability 
of all the results of the investigations performed to determine  etiology of the LFT 
abnormalities.   
A potential DILI (Hy’s law) case becomes a confirmed cas e only after all results of 
reasonable investigations have been received and have excluded an alternative etiology. 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 85 10.7. Appendix 7: ECG Findings of Potential Clinical Concern 
ECG Findings That May Qualify as Adverse Events (AEs) 
x Marked sinus bradycardia (rate <40 bpm) lasting minutes. 
x New PR interval prolongation >280 msec. 
x New prolongation of QTcF to >480 msec (absolute) or by ≥60 msec from 
baseline. 
x New-onset atrial flutter or fibrillation, with controlled ventr icular response rate: ie, 
rate <120 bpm. 
x New-onset type I second-degree (Wenckebach) atrioventricular (A V) block of 
>30 seconds ’ duration. 
x Frequent premature ventricular complexes (PVCs), triplets, or short intervals 
(<30 seconds) of consecutive ventricular complexes. 
ECG Findings That May Qualify as Serious Adverse Events (SAEs) 
x QTcF prolongation >[ADDRESS_780447]-T changes suggestive of myocardial ischemia. 
x New-onset left bundle branch block (QRS >120 msec). 
x New-onset right bundle branch block (QRS >120 msec). 
x Symptomatic bradycardia.  
x Asystole: 
x In awake, symptom-free participants in sinus rhythm, with docum ented 
periods of asystole ≥3.0 seconds or any escape rate <[ADDRESS_780448] 5 seconds or longer.  
x Atrial flutter or fibrillation, with rapid ventricular response  rate: rapid = rate 
>120 bpm. 
x Sustained supraventricular tachycardia (rate >120 bpm) ( “sustained ” = short 
duration with relevant symptoms or lasting >1 minute). 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 86 x Ventricular rhythms >30 seconds ’ duration, including idioventricular rhythm (rate 
<40 bpm), accel erated idioventricular rhythm (40< x <100), and 
monomorphic/polymorphic ventricular tachycardia >100 bpm (such as torsades 
de pointes). 
x Type II second-degree (Mobitz II) AV block. 
x Complete (third-degree) heart block. 
ECG Findings That Qualify as Serious Adverse Events 
x Change in pattern suggestive of new myocardial infarction.  
x Sustained ventricular tachyarrhythmias (>30 seconds ’ duration). 
x Second- or third-degree AV block requiring pacemaker placement.  
x Asystolic pauses requiring pacemaker placement. 
x Atrial flutter or fibrillation with rapid ventricular response requiring 
cardioversion. 
x Ventricular fibrillation/flutter. 
x At the discretion of the investigator, any arrhythmia classifie d as an adverse 
experience. 
The enumerated list of major events of potential clinica l conce rn are recommended as “alerts ” o r 
notifications from the core ECG la b oratory to the investigator a nd Via tris study team, a nd not to be 
considered as all inclusive of what to be reported as AEs/SAEs.  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 87 10.8. Appendix 8: Clinical Opi[INVESTIGATOR_591802], circle the number that best describes the patien t' s signs or symptom.  Rate on 
just the apparent relationship to opi[INVESTIGATOR_2533].  For examp le, if pulse rate is increased 
because the patient was jogging just prior to assessment, the i ncrease pulse rate would not 
add to the score. 
Patient' s Name: [CONTACT_140969] t e a n d Tim e:   
Reason for this assessment: 
Resting Pulse Rate:                    beats/minute                  
Measured after patient is sitting or lying for one  minute  
0 pulse rate 80 or below  
1 pulse rate 81 -100  
2 pulse rate 101 -120  
4 pulse rate greater than 1 20 GI Upset:  over last 1/2 hour  
0 no GI symptoms  
1 stomach cramps  
2 nausea or loose stool  
3 vomiting or diarrhea  
5 multiple epi[INVESTIGATOR_182072]:  over past 1/2 hour not accounted for by [CONTACT_182136].   
0 no report of chills or flushing  
1 pa rticipant report of chills or flushing  
2 flushed or observable moistness on face  
3 beads of sweat on brow or face  
4 sweat streaming off face Tremor  observation of outstretched hands  
0 no tremor  
1 tremor can be fe lt, but not observed  
2 slight tremor observable  
4 gross tremor or muscle twitching  
Restlessness  Observation during assessment   
0 a ble to sit still  
1 reports difficulty sitting still, but is a ble to do so  
3 frequent shifting or extraneous movements of legs/ar ms  
5 una ble to sit still for more than a few seconds  Yawning  Observation during assessment  
0 no yawning  
1 yawning once or twice during assessment  
2 yawning three or more times during 
assessment  
4 yawning sever al times/minute 
Pupil size   
0 pupi[INVESTIGATOR_2658]  
1 pupi[INVESTIGATOR_2659]  
2 pupi[INVESTIGATOR_591803]  
5 pupi[INVESTIGATOR_591804]   
0 none  
1 pa tient reports increasing irrita bility or 
anxiousness  
2 patient obviously irritable or anxious  
4 patient  so irritable or anxious that 
pa rticipation in the a ssessment is difficult 
Bone or Joint aches  if patient was having pain 
previously, only the additional component attributed to 
opi[INVESTIGATOR_182076]   
0 not present  
1 mild diffuse discomfort  
2 patient reports severe diffuse aching of joints/muscles  
[ADDRESS_780449] eyes  
2 nose running or tearing  
4 nose constantly running or tears streaming down cheeks Tota l Score __________ 
 
The total score is the sum of all 11 items  
 
Initia ls of person completing 
a ssessment:______ 
Score: 5- 12 = mild; 1 3-24 = moderate; 25-36 = moderately seve re; more than 36 = severe withdr awal 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 88 10.9. Appendix 9: Abbreviations 
The following is a list of abbreviations that may be used in th e protocol. 
Abbreviation Term 
Abs absolute 
ACLS advanced cardiac life support 
AE adverse event 
ALT alanine aminotransferase 
ANOVA analysis of variance 
AST aspartate aminotransferase 
AUC area under the curve 
AUC inf area under the plasma concentration-time 
profile from time [ADDRESS_780450] automated battery  
CFR Code of Federal Regulations 
CIOMS Council for International Organizations of Medical Sciences 
CK creatine kinase 
Cmax maximum observed concentration 
CO 2 carbon dioxide (bicarbonate) 
COWS clinical opi[INVESTIGATOR_591805] 
C-SSRS Columbia Suicide Severity Rating Scale 
CSR clinical study report 
CT clinical trial 
CTMS clinical trial management system 
CV coefficient of variation 
CYP Cytochrome P450 
DAI Drug Administration Instructions 
DILI drug-induced liver injury 
DMC data monitoring committee 
PF-[ADDRESS_780451] European Clinical Trials Database 
FDA Food and Drug Administration 
FSH follicle-stimulating hormone 
GABA gamma-aminobutyric acid 
GCP Good Clinical Practice 
GGT gamma-glutamyl transferase 
HAV IgM/G Hepatitis A virus imm unoglobulin M/G 
HBcAb hepatitis B core anti body 
HBsAg  hepatitis B surf ace antigen 
HCVAb hepatitis C anti body 
HIPAA Health Insurance Portability and Accountability Act 
HIV human immunodeficiency virus 
HR heart rate 
HRT hormone replacement therapy 
IB investigator’s brochure  
ICD informed consent document 
ICH International Council for Harmonisation 
IND investigational new drug application 
INR international normalized ratio 
IP  investigational product  
IRB institutional review board 
IUD intrauterine device 
IUS intrauterine hormone-releasing system 
IV intravenous 
IVRS Interactive Voice Response System   
LFT liver function test 
MCH mean corpuscular hemoglobin 
MCHC mean corpuscular hemoglobin concentration 
MCV mean corpuscular volume 
MHP mental health professional 
msec millisecond 
N/A not applicable 
PCD primary completion date 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 90 Abbreviation Term 
CRU Clinical Research Unit 
PD pharmacodynamic(s) 
PK pharmacokinetic(s) 
PR pulse rate 
PT prothrombin time 
PVC premature ventricular complex 
Q1 first quartile 
Q3 third quartile 
QTc corrected QT 
QTcB corrected QT using Bazett’s method  
QTcF corrected QT using Fridericia’s method  
qual qualitative 
RBC red blood cell 
RNA ribonucleic acid 
RR respi[INVESTIGATOR_591806] [ADDRESS_780452] upper limit of normal 
US [LOCATION_002] 
USPI [INVESTIGATOR_591807]-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 91 10.10.  Appendix 10: VAS Assessment Methods 
The overall appearance of all VAS items utilizing the Cambridge  Neuropsychological Test 
Automated Battery (CANTAB) or using comparable software will be  similar to screen 
images shown below.  The participants will be trained to use th e software at the site. 
Image A: screen display of Drug Liking VAS 
 
The questions and anchors on VAS items will be modified appropr iately to reflect study 
specific questions as shown in Images B-D (see Table 7). 
 

PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 92 Image B: screen display of High VAS 
 
Image C: screen display of Overall Drug Liking VAS 
 

PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 93 Image D: screen display of Take Drug Again VAS 
 
 
Table 7. Other Subjective Effects Visual Analog Scales  
SCALE DESCRIPTION STATEMENT TEXT RESPONSE ANCHORS 
Good Drug Effects I can feel good drug 
effects  0: Not at all 
100: Extremely 
Bad Drug Effects I can feel bad drug effects 
Feeling Sick I am feeling sick 
Nausea I am feeling nausea 
Any Drug Effects I can feel any drug effect 
Sleepy I am feeling sleepy 
Dizzy I am feeling dizzy 
 

PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 94 10.11.  Alertness/Sedation Assessment 
The Modified Observer’s Assessment of Alertness/Sedation scale or comparable scale will 
be used for the assessment of alertness/sedation (see Table 8).   
 
Table 8. Modified Observer’s Assessment of Alertness/Sedation Scale  
Responsiveness Numerical score 
Responds readily to name [CONTACT_154992] 5 
Lethargic response to name [CONTACT_154992] 4 
Responds only after name [CONTACT_248794]/or repeatedly 3 
Responds only after mild prodding or shaking 2 
Responds only after painful trapezius squeeze* 1 
No response after painful trapezius squeeze 0 
*Purposeful response, not withdrawal. 
 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 95 10.12.  Appendix 12: Alternative Measures During Public Emergencies 
The alternative study measures described in this section are to  be followed during public 
emergencies, including the COVID-19 pandemic. This appendix app lies for the duration of 
the COVID-19 pandemic globally and will become effective for ot her public emergencies 
only upon wr itten notification from Viatris.  
Use of these alternative study measures are expected to cease u pon the return of business as 
usual circumstances (including the lifting of any quarantines a nd travel bans/advisories).  
10.12.1.  Eligibility 
Not applicable 
10.12.2.  Telehealth Visits  
Not applicable  
10.12.3.  Alternative Facilities for Safety Assessments   
Not applicable  
10.12.4.  Study Intervention  
If the safety of a trial participant is at risk because they ca nnot complete required evaluations 
or adhere to critical mitigation steps, then discontinuing that  participant from study 
intervention must be considered. For participant discontinuatio n reporting in the CRF: select 
the most appropriate status for discontinuation; if the discont inuation is associated with the 
current COVID- 19 pandemic, enter “COVID -19” in the “Specify Status” field.  
10.12.5.  Home Health Visits  
Not applicable 
10.12.6.  Adverse Events and Serious Adverse Events 
If a participant has COVID-19 during the study, this should be reported as an adverse event 
(AE) or serious adverse events (SAE) and appropriate medical in tervention provided.  
It is recommended that the investigator discuss temporary or pe rmanent discontinuation of 
study intervention with the study medical monitor.  
10.12.7.  Efficacy Asse ssments 
Not applicable 
10.12.8.  Independent Oversight Committees 
Not applicable 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 96 10.13.  Appendix 13: Summary of Changes 
Protocol Title A phase 4, randomized, double-blind, double-dummy, placebo- and  
active -controlled, single-dose, five- way crossover study evaluating the 
Abuse Potential of three Doses of Neurontin® taken orally in healthy, 
non-drug dependent participants with sedative drug abuse experience  
Product Neurontin® (gabapentin) 
Protocol 
Number  A9451181  
Study Type Phase 4 
Version 5.0 
Protocol Date 29 Apr 2022 
Legal/Filing 
Sponsor  Viatris Specialty LLC 
[ADDRESS_780453]  
Morgantown, WV [ZIP_CODE] 
 
 
 
  
 
 
 
 
 
 
  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 97 Table 9. Summary of changes from Protocol dated 14 May 2020 to Protocol 2.0 dated 11 Dec 2020 
Section  Old Text  
(Protocol dated 14 May 2020 New Text  
(Protocol Version 2.0 dated 11 Dec 2020) Rationale for 
amendment 
Administrative 
Changes  
Sponsor and 
Sponsor contacts 
details updated Missing 
Sponsor name ‘[COMPANY_007]’  Added 
Upjohn US [ADDRESS_780454]. Sandeep Jagtap  
Clinical Strategy Lead – CNS 
Global Clinical Strategy & Innovation  
David Gillogly  
Head, Global Clinical Operations  
The sponsor name [CONTACT_366595] ‘[COMPANY_007]’ to 
‘Upjohn’ wherever applicable throughout the 
protocol The sponsor for this 
study is changed from 
‘[COMPANY_007]’ to ‘Upjohn 
US 1 LLC’  
Administrative 
changes are made to 
include updated 
Sponsor details and 
authorized sponsor 
protocol approvers 
Section 1.3 
Schedule of 
Activities 
(Table:1 footer) Missing text for bullet h. vital signs 
will be recorded at pre -do rst 
naloxone dose) and at 5 m s, 0.25, 
0.5, 1, 1.5, and 2 hours follo ng the 
second dose of naloxone.  Added “vital signs will be recorded at pre -
ose (first naloxone dose) and at 5 minutes, 
.25, 0.5, 1, 1.5, and 2 hours following the 
econd dose of naloxone. Vital signs w ill be 
ecorded at nominal time points ± 5 minutes”  The changes are 
made to p rovide 
clarification  
 
Section 1.3 
Schedule of 
Activities  
(Table:2 -footer) Missing “12 -lead Electrocar gram” 
measurements at Day -1 (baseline) and 
Day 4 during Treatment Phase.  
 dded “12 -l ead Electrocardiogram” 
easurements (Conducted after a resting 
eriod of at least 10 minutes in a supi[INVESTIGATOR_12251]) at Day -1 (baseline) and Day 4 
during Treatment Phase.  The changes are 
made to add missing 
and typographical 
error  
 

PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 98 Missing text for bullet g. Vital signs 
(including pulse rate, systolic and 
diastolic blood pressures are measured 
at the nominal time points after a 
resting period of at least 5 minutes in a 
sitting position. Temperature (oral or 
with a temporal infrared scanner) will 
be measured on Day -1 of each 
Treatment Visit only. Added “Vital signs (including pulse rate, 
systolic and diastolic blood pressures are 
measured at the nominal time points after a 
resting period of at least 5 minutes in a sitting 
position. Temperature (oral or with a 
temporal infrared scanner) will be measured 
on Day -1 of each Treatment Visit only. Vital 
signs will be recorded at nominal time points 
± 5 minutes”  The changes are 
made to add missing 
and typographical 
error  
Section 2.1 Study 
Rationale From 
(4th paragraph): Epi[INVESTIGATOR_591808], particularly among 
individuals with a history of opi[INVESTIGATOR_591809]. Gabapentin abuse is reported 
both alone ( ie, without other drugs), 
and in conjunction with opi[INVESTIGATOR_591810] ‘high’ obtained from 
opi[INVESTIGATOR_2438].1,[ADDRESS_780455] that gabapentin is recorded on 
death certificates suggesting drug 
overdose, both as the primary and 
contributory causes of death, and 
reported with and without other drugs 
like opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_1651], and 
alcohol.1,5 -7 This clinical tria l will 
evaluate gabapentin in a cross -over 
design with comparison to placebo and 
a positive control, di azepam, regarding 
abuse -related subjective responses, 
physiological responses (including an 
assessment of respi[INVESTIGATOR_2341]), 
and drug pharmacokinetics in a Epi[INVESTIGATOR_591811], 
particularly among individuals with a history 
of opi[INVESTIGATOR_2554]. Gabapentin abuse is reported 
both alone ( ie, without other drugs), and in 
conjunction with opi[INVESTIGATOR_483240] 
‘high’ obtained from opi[INVESTIGATOR_2438].1,[ADDRESS_780456]-
authorization safety study (PASS) to evaluate 
gabapentin in a cross -over design with 
comparison to placebo and a positive control, 
diazepam, regarding abuse -related subjective 
responses, physiological responses (including 
an assessment of respi[INVESTIGATOR_2341]), and 
drug pharmacokinetics in a healthy non -drug The changes were 
made for clarification 
(modifying the last 
sentence from “ This 
clinical trial will 
evaluate gabapentin 
in a cross -over 
design -----” to “ As a 
consequence, the 
FDA has required this 
post-authorization 
safety study (PASS) 
to evaluate 
gabapentin in a cross-
over design  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 99 healthy non-drug dependent 
population with drug abuse experience 
with sedative drugs. dependent population with drug abuse 
experience with sedative drugs.  
Section 5.2 
Exclusion 
Criteria  Participants are heavy smokers (>20 
cigarettes per day) and/or use e -
cigarettes, pi[INVESTIGATOR_27442], cigars, chewing 
tobacco, nicotine topi[INVESTIGATOR_113040], 
nicotine gum, or nicotine lozenges. Participants are heavy smokers or users of 
other types of nicotine products (>20 
cigarettes equivalents per day)  Changes are made to 
provide clarification 
 
Section 5.2 
Exclusion 
Criteria and  
Section 5.3 
Lifestyle 
Considerations Section 5.2: Participants are unable to 
abstain from smoking for at least [ADDRESS_780457] 8 hours after 
study drug administration.  
Section 5.3: Participants will not be 
permitted to smoke from at least [ADDRESS_780458] 8  hours after 
dosing in the Qualification and 
Treatment Phases. Section 5.2: Participants are unable to abstain 
from smoking for at least [ADDRESS_780459] 8 hours after study drug 
administration.  
Section 5.3: Participants will not be permitted 
to smoke from at least [ADDRESS_780460] 8  hours after dosing in the Qualification 
and Treatment Phases.  The changes are 
made due to a 
typographical error 
(e.g. From “at least 1 
hour before” To “at 
least 2 hours before”).  
 
Section 5.3.2 
Caffeine, 
Alcohol, and 
Tobacco  The use of oral or chewed tobacco 
and/or nicotine -containing products 
(including topi[INVESTIGATOR_113040]) is not 
permitted for the entire st udy  The use of oral or chewed tobacco and/or 
nicotine -containing products (including 
topi[INVESTIGATOR_113040]) is not permitted from at least 
[ADDRESS_780461]  At screening, participants will be 
assigned a Single Participant Identifier 
number via an automated Interactive 
Voice Response System (IVRS) or 
equivalent system provided by [CONTACT_4618]. 
Following screening the participants 
will be ra ndomized. The 
randomization number for the At screening, participants will be assigned a 
subject screening identification number 
(SSID) via an automated Interactive 
Response Technology (IRT) or equivalent 
system . 
Following screening the participants will be 
randomly assigned a qualification 
randomization number (QRN)via the IRT or Changes are made to 
provide clarity for 
changes in study 
conduct  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 100 participant will be allocated via the 
IVRS or equivalent system using a 1:1 
randomization within each of the 
randomization strata. This number will 
be retained throughout the study and 
will correspond to a blinded treatment 
schedule determined by a [COMPANY_007] 
generated randomization code.  
 equivalent system using a 1:1 randomization. 
The QRN will be retained throughout the 
study and w ill corres pond to the blinded 
qualific ation phase. 
After satisfactory completion of the 
qualification phase, participants will 
randomly be assigned a study randomization 
number (SRN) via the IRT or equivalent 
system using a 1:1 randomization for the 
treatment phase. The SRN will be retained 
throughout the study and w ill correspond to 
the blinded treatment sequence. 
Section 6.3.2 
Breaking the 
Blind  
From (the 3rd and 
4th paragraphs): 
 The method for breaking the blind in 
this study w ill be manual.  A sealed 
envelope that contains the study 
intervention assignment(s) for each 
participant will be provided to the 
investigator.  The sealed envelope will 
be retained by [CONTACT_093] (or 
representative) in a secured area.  In 
case of an emergency, the investigator 
has the sole responsib ility for 
determining if unblinding of a 
participant’s treatment assignment is 
warranted.  Participant safety must 
always be the first consideration in 
making such a determination.  If the 
investigator decides that unblinding is 
warranted, the investigator should 
make every effort to contact [CONTACT_462768] a The IRT will be programmed with 
blind -breaking instructions.  In case of an 
emergency, the investigator h as the sole 
responsib ility for determining if unblinding of 
a participant’s treatment assignment is 
warranted.   Participant safety must always be 
the first consideration in making such a 
determination.   If the investigator decides that 
unblinding is warran ted, the investigator 
should make every effort to contact [CONTACT_591848] a participant’s treatment 
assignment unless this could delay further 
management of the participant.   If a 
participant’s treatment assignment is 
unblinded, the sponsor must be notified 
within 24 hours after breaking the blind.   The 
date and reason that the blind was broken The changes are 
made to transfer 
responsib ility of an 
IRT to a CRO and 
provide a flexibility 
of randomization to 
the CRO.  
 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 101 participant’s treatment assignment 
unless this could delay further 
management of the participant.  If a 
participant’s trea tment assignment is 
unblinded, the sponsor must be 
notified within [ADDRESS_780462] be fully 
documented and entered on the CRF. 
Once the study is complete, all 
envelopes (sealed and opened) must be 
inventoried and retained until 
authorization for destruction has been 
provided.  must be recorded in the source documentation 
and data collection tool (DCT).  
The study -specific IRT reference manual and 
IP manual  will provide the contact 
[CONTACT_591849].  
 
Section 8.2.2 
Vital Signs  
From (3rd 
paragraphs):  
 Pulse and respi[INVESTIGATOR_109651], oxygen 
saturation, diastolic and systolic blood 
pressure will be monitored 
continuously post -drug. These 
measures are done in abuse liab ility 
testing to ensure safety.  Pulse and respi[INVESTIGATOR_109651], oxygen saturation, 
diastolic and systolic blood pressure w ill be 
monitored post -drug (see SoA). These 
measures are done in abuse liab ility testing to 
ensure safety.  The changes are 
made due to a 
typographical error. 
 
Section [IP_ADDRESS] 
Continuous 
Cardiac 
Monitoring by 
[CONTACT_591850] w ill be recorded 
and reviewed by [CONTACT_591851].  The time, 
duration, and description of the 
clinically significant event will be 
recorded in the CRF.  In addition, a 
printed record of the tracing(s) of the 
clinically significant rhythm(s) will be Continuous cardiac monitoring w ill be 
performed as noted in the SoA.  The time, 
duration, and description of any clinically 
significant abnormal rhythm w ill be reported 
as an adverse event.  
 The change are made 
because, as part of 
standard of care, an 
ECG will be 
performed for any 
clinically significant 
abnormal rhythm 
making telemetry 
record storage and 
data transfer 
PF-[ADDRESS_780463] 
and the system connected prior to 
dosing. capability 
unnecessary.  
 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 103 Section 8.6.2 
Visual Analog 
Scale (VAS)  
 Missing a text at the end of 1st 
paragraph for the VAS testing time 
window as “All VAS testing w ill be 
administered at the nominal time 
points ±5 minutes.”  Add a text at the end of 1st paragraph for the 
VAS testing time window as “All VAS 
testing will be administered at the nominal 
time points ±5 minutes.”  The change are made 
to provide 
clarification.  
 
Section 10.1.5 
Dissemination of 
Clinical Study 
data Removed www.pfizer.com 
[COMPANY_007] posts public disclosure synopsis, 
a clinical study report (CSR) in which 
any data that could be used to identify 
individual participants have been 
removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies 
at the same time the US Basic Results 
document is posted to 
www.clinicaltrials.gov. No information added This information is 
removed due to 
change of study 
sponsor from [COMPANY_007] 
to Upjohn.   
Section 10.1.10 
Sponsor’s 
Qualified 
Medical 
Personnel  Removed  
For sites other than a [COMPANY_007] CRU, the 
contact [CONTACT_591852] a 
participant calls that number, he or she 
will be directed back to the 
investigator site. No information added This statement is 
removed due to 
change of study 
sponsor from [COMPANY_007] 
to Upjohn.  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 104 Section 
10.13.  Appendix 
13: Alternative 
Measures 
During  Public 
Emergencies  None (No appendix information 
available in the protocol regarding 
COVID -19) 
 10.13. Appendix 13: Alternative Measures 
During  Public Emergencies 
The alternative study measures described in 
this section  are to be followed during public 
emergencies, including the COVID -19 
pandemic. This appendix applies 
for the duration of the COVID- 19 pandemic 
globally and will become effective for other 
Public emergencies only upon wr itten 
notification from Upjohn.  
Use of these alternative study measures are 
expected to cease upon the return of business 
as usual circumstances (including the lifting 
of any quarantines and travel 
bans/advisories).  
10.12.[ADDRESS_780464] assessment 
of alternative 
measures due to 
COVID -19. 
 
 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 105 participant discontinuation reporting in the 
CRF: select the most appropriate status for 
discontinuation; if the discontinuation is 
associated with the current COVID -19 
pandemic, ente r “COVID -19” in the “Specify 
Status” field.   
10.12.5  Home Health Visits  
Not applicable  
10.12.6 Adverse Events and Serious Adverse 
Events  
If a participant has COVID -19 during the 
study, this should be reported as an adverse 
event (AE) or serious adverse events (SAE) 
and appropriate medical intervention 
provided.  
It is recommended that the investigator 
discuss temporary or permanent 
discontinuation of study intervention with the 
study medical monitor.  
10.12.7 Efficacy Assessments  
Not applicable  
10.12.8 Independent Oversight Committees 
Not applicable  
 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 106 Table 10. Summary of changes from Protocol version 2.0 dated 11  Dec 2020 to Protocol version 3.0 dated 26 Feb 2021 
Section  Old Text  
(Protocol Version 2.0 dated 11 Dec 
2020) New Text  
(Protocol Version 3.0 dated 26 Feb 2021) Rationale for 
amendment  
Section 1.3,  
Table 2 schedule 
of activities for 
treatment phase There is ‘X’ denoting VAS pre -dose 
assessment for good drug effects, bad 
drug effects & any drug effects in the 
treatment phase.  
 ‘X’ denoting VAS pre -dose assessment for 
good drug effects, bad drug effects & any 
drug effects in the treatment phase is deleted. Correction of 
inadvertent error  
Section 5.2 
Exclusion 
Criteria # 11: Herbal supplements, herbal 
medications and hormone replacement 
therapy must be discontinued at least 
[ADDRESS_780465] dose of study medication.  
(hormone replacement therapy is deleted) Correction of 
typographical error 
 
 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 107 Table 11. Summary of changes from Protocol version 3.0 dated 26  Feb 2021 to Protocol version 4.0 dated 04 Aug 2021 
Section  Old Text  
(Protocol Version 3.0 dated 26 Feb 2021) New Text  
(Protocol Version 4.0 dated 04 Aug 
2021) Rationale for 
amendment  
Administrative 
change  Upjohn US [ADDRESS_780466] 
details updated Sandeep Jagtap, MD 
Clinical Strategy Lead – CNS
Viatris, Bangalore  
Prestige Platina, Block 3, Ka nah
Village,  
Outer Ring Road, Bangalore 60 7, 
K
arnataka, INDIA  
[EMAIL_11275], PhD 
al Development Lead  
s 
very Park  
gate Road  
wich, Kent, CT13 9ND  
ited Kingdom  
.[EMAIL_11276]  Change to Sponsor 
personnel  
Section 5.1 
Inclusion 
criterion #[ADDRESS_780467] 
enrolment  
Section 5.1 
Inclusion 
criterion #[ADDRESS_780468] be recreational sedativ
users, defined as those report  
sedative agent (eg, barbiturat
benzodiazepi[INVESTIGATOR_1651]) for its intox
on at least [ADDRESS_780469] once in the 8 wee
Screening Visit (Visit 1), but 
signs of dependence and are ing 
treatment for their sedative uParticipants must be recreational sedative 
, defined as those reporting using a 
ive agent (eg, barbiturates, 
diazepi[INVESTIGATOR_1651]) for its intoxicating 
ts on at least [ADDRESS_780470] once in the 12 weeks before 
 Screening Visit (Visit 1), but who have 
 signs of dependence and are not 
king treatment for their sedative use Aligning the 
definition of an 
experienced 
recreational sedative 
user to other similar 
Human Abuse 
Potential studies in 
recreational sedative 
users to facilitate 
subject enrolment 

PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 108 Section 5.2 
Exclusion 
criterion #[ADDRESS_780471], if deemed necessary:  
x Aspartate aminotransferase (AST) or 
alani ne aminotransferase (ALT) level Ŏ
1.5 灤 upper limit of normal (ULN) 
Total bilirubin level Ŏ 1.[ADDRESS_780472]; 
participants with a history of Gilbert 瀠s 
syndrome may have direct b ilirubin 
measured and would be eligible for this 
study provided the direct b ilirubin level is 
ō ULN Participants with ANY of the following 
abnorma lities in clinical laboratory tests at 
screening, as assessed by [CONTACT_591853] a 
single repeat test, if deemed to be 
clinically significant in the opi[INVESTIGATOR_1070]: 
x Aspartate aminotransferase (AST) or 
alanine aminotransferase (ALT) level 
Ŏ1.5 灤 upper limit of normal (ULN) 
Total bilirubin level Ŏ 1.[ADDRESS_780473]; 
participants with a history of Gilbert 瀠s 
syndrome may have direct b ilirubin 
measured and would be eligible for this 
study provided the direct b ilirubin level is 
ō ULN Clarification to allow 
the investigator to 
apply clinical 
judgement  
Administrative 
change  
Appendix 13 
Table 
numbering re-
ordered  Table 9. Summary of changes from 
Protocol version 2.0 dated 11 Dec 2020 to 
Protocol version 3.0 dated 26 Feb 2021 
Table 10. Summary of changes from 
Protocol dated 14 May 2020  to Protocol 
2.0 dated 11 Dec 2020  
 Table 9. Summary of changes from 
Protocol dated 14 May 2020  to Protocol 
2.0 dated 11 Dec 2020  
Table 10. Summary of changes from 
Protocol version 2.0 dated 11 Dec 2020 to 
Protocol version 3.0 dated 26 Feb 2021 To enable new 
amendments to be 
assigned successively 
higher table numbers 
in date order  
 
 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 109 Table 12. Summary of changes from Protocol version 4.0 dated 04  Aug 2021 to Protocol version 5.0 dated 29 Apr 2022 
Section  Old Text  
(Protocol Version 4.0 dated 04 Aug 2021) New Text  
(Protocol Version 5.0 dated 29 Apr 
2022) Rationale for 
amendment  
Administrative 
change  
Sponsor details 
throughout the 
document  Upjohn US [ADDRESS_780474] udy design involving 
approximately 40 participants (4 
participates in each sequence) to ensure at 
least [ADDRESS_780475] udy design involving 
approximate ly 50 participants (5 
participants in each sequence) to ensure at 
least 32 participants meeting the definition 
of the Modified Completer Population 
complete the treatment phase of the study 
as shown in Figure 1  Increasing the 
number of subjects enrolled 
to ensure 
sufficient subjects 
meeting the newly-
defined Modified 
Completer Population 
Table 2, 
footnote g  Vital signs (including pulse rate, systolic 
and diastolic blood pressures are measured 
at the nominal time points after a resting 
period of at least 5 minutes in a sitting 
position.  Temperature (oral or with a 
temporal infrared scanner) will be 
measured on Day -1 of each Treatment 
Visit only. Vital signs will be recorded at 
nominal time points ±5 min  Vital signs (including pulse rate, systolic 
and diastolic blood pressures are measured 
at the nominal time points after a resting 
period of at least 5 minutes in a sitting 
position.  Temperature (oral or with a 
temporal infrared scanner) will be 
measured on Day -1 of each Treatment 
Visit only. Vital signs will be recorded at 
nominal time points ±[ADDRESS_780476] -dose, within 
±[ADDRESS_780477]-dose, and within ±[ADDRESS_780478] -dose 
Table 2, 
footnote p  None (new text added) Subjects may be discharged after 
completion of Day [ADDRESS_780479] 
enrollment  
Section 4.1 This will be a ra ndomized, double-blind, 
double -dummy, placebo- and active 
controlled, 5 treatment, 10 sequence, 5 
period crossover single dos e, Williams 
square design study in healthy adult, non 
drug dependent male and female 
participants with drug abuse experience 
with sedative drugs …This study w ill 
randomize approximately [ADDRESS_780480] udy in healthy 
adult, non drug dependent male an d 
female participants with drug abuse 
experience with sedative drugs …This 
study w ill randomize approximately [ADDRESS_780481] 32 
participants meeting the definition of the 
Modified Completer Population complete  
the Treatment Phase of the  study. Adding “multi -
center” in the study 
description  and 
increasing the number 
of subjects enrolled to 
ensure sufficient 
subjects meeting the 
newly -defined 
Modified Completer 
Population  
Section 4.1 x Visits 3 to 7, Treatment Phase: 
x Each visit will require an inpatient 
stay at the CRU of 4 nights. 
x For the entire study, 23 overnight 
inpatient stays will be required x Visits 3 to 7, Treatment Phase: 
x Each visit will require an inpatient 
stay at the CRU of 3 or 4 nights. 
Subjects may be discharged after 
completion of 48 h postdose 
assessments and return for 72 h 
postdose assessments on an 
ambulatory basis, at the discretion of 
the investigator. Reducing the number 
of residential nights 
from 4 to 3 , at the 
investigator’s 
discretion,  to 
facilitate subject 
enrollment  
PF-[ADDRESS_780482] abstain 
from using THC 
while resident in the 
clinic  
Section 5.3.4 At time points indicated in the schedule of 
activities (SoA), the investigator or 
designee will inform the participant of the 
need to use highly effective contraception 
consistently and correctly and document 
the conversation and the participant’s 
affirmation in the participant’s chart 
(participants  need to affirm their consistent 
and correct use of at least 1 of the selected 
methods of contraception)  At time points indicated in the schedule of 
activities (SoA), the investigator or 
designee will inform the participant of the 
need to use effective contraception 
consistently and correctly and document 
the conversation and the participant’s 
affirmation in the participant’s chart 
(participants need to affirm their 
consistent and correct use of at least 1 of 
the selected methods of contraception) Change to reflect the 
addition of further  
forms of acceptable 
female contraception, 
in order to facilitate 
subject enrollment 
Section 8.2.2 The same arm (preferably the dominant 
arm) will be used throug hout the study.   The same arm (preferably the dominant 
arm) should be used throughout the study.   Change from the 
mandatory 
requirement to a 
recommendation 
Section 8.5 Collection of samples up to and including 
10 hours after dose administration that are 
obtained within 10% of the nominal time 
(eg, within 6 minutes of a 60 minute 
sample) relative to dosing will not be 
captured as a protocol deviation, as long as 
the exact  time of the collection is noted on Collection of samples up to and including 
10 hours after dose administration that are 
obtained within 5 minutes or 10% of the 
nominal time (eg, within 6 minutes of a 60 
minute sample), whichever is greater, 
relative to dosing will not be captured as a 
protocol deviation, as long as the exact 
time of the collection is noted on the Redefining the 
permitted time 
windows for PK 
sampling  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 112 the source document and data collection 
tool (eg, CRF).   source document and data collection tool 
(eg, CRF).   
Section 8.6.2 All VAS testing will be administered at the 
nominal time points ±5 minutes . All VAS testing will be administered at 
the nominal time points ±[ADDRESS_780483]-
dose, within ±[ADDRESS_780484]- dose, and within ±[ADDRESS_780485] -dose. Increasing the 
permitted time 
windows for vital 
signs assessments 
Section 9.1 Study Validation: 
The sensitivity and integrity of the st udy 
will be validated by [CONTACT_591854], the pos itive control 
(C), to the pl acebo:  
H0: μC - μP ō 煩1 versus Ha: μC - μP > 煩
1 where 煩1 >15 . 
Gabapentin versus diazepam:  
1. Does gabapentin (T) produce mean 
responses that show less abuse potential 
than diazepam?  
H0: μC - μT ō 煩2 versus Ha: μC - μT > 煩
2 where 煩2 Ŏ0. 
Gabapentin versus placebo (Primary):  Study Validation: 
The sensitivity and integrity of the st udy 
will be validated by [CONTACT_591854], the pos itive 
control (C), to the placebo (P):  
H0: μC - μP ō 煩1 versus Ha: μC - μP > 
煩1 where 煩1 =15. 
Gabapentin versus diazepam:  
1. Does gabapentin (T) produce mean 
responses that show less abuse potential 
than diazepam?  
H0: μC - μT ō 煩2 versus Ha: μC - μT > 
煩2 where 煩2 =0. 
Gabapentin versus placebo (Primary): Corrections to the 
three equations  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 113 2. Does gabapentin (T) produce mean 
responses that show abuse potential similar 
to placebo?  
H0: μT - μP Ŏ 煩3 versus Ha: μp - μT < 煩
3 where 煩3 >11.  2. Does gabapentin (T) produce mean 
responses that show abuse potential 
similar to placebo?  
H0: μT - μP Ŏ 煩3 versus Ha: μT - μP < 
煩3 where 煩3 =11.  
Section 9.[ADDRESS_780486] 20% w ill be 
females to ensure that the findings are 
valid across different populations.  Increasing the 
number of subjects 
enrolled to ensure 
sufficient subjects 
meeting the newly-
defined Modified 
Completer Population 
and to specify the 
proportion of females 
Section 9.[ADDRESS_780487] 
dose response on the VAS for Drug 
Liking within 2 hours of Tmax for each 
treatment g roup: ie, at least one VAS 
response within the interval 0-3h 
postdose (assuming the Tmax of 20 mg 
diazepam is 1h) and at least one VAS 
response within the interval 1-5h 
postdose (assuming the Tmax of 
600/1200/1800 mg gabapentin is 3h).  Modifying the 
definition of the 
Completer Population 
(upon which other 
analysis sets are 
defined) to specify 
the minimum 
required post -dose 
responses required 
within the Tmax time 
periods specific to the 
two study drugs, in 
line with FDA 
guidance on assessing 
PF-[ADDRESS_780488] the PD 
conclusions of the study.  Prior to 
unblinding the Treatment Phase data, the 
sponsor (or designee) w ill identify 
proto col violations or adverse events that 
would disqualify a participant from the 
evaluable population and determine 
which participants or participant visits 
will be excluded.  This population will be 
analyzed as randomized. 
All PD analyses will be performed using 
the Modified Completer Population and all 
available post dose data; these will be the 
primary PD analyses.  Key PD analyses 
may be repeated on the Evaluable 
Population using all available post -dose 
data.  This population will be analyzed as 
randomized. 
x The Modified Completer Population 
will include all ra ndomized participants 
in the Completer Population, but w ill 
exclude any participant who meet either 
or both of the following criteria for 
Drug Liking VAS: 
1. Emax scores are wit hin a 5 point 
difference across all five treatments 
(ie, Maximum Emax score 瀤 
Minimum Emax score ō5); 
2. Emax(P) > 60 AND Emax(P) - 
Emax(Dia) Ŏ5; 
where Emax(P) and Emax(Dia) are the 
VAS Emax scores for placebo and 
diazepam [ADDRESS_780489] the PD conclusions of 
the study.  Prior to unblinding the 
Treatment Phase data, the sponsor (or 
designee) will identify protocol 
violations or adverse events that would 
disqualify a participant from the 
evaluable population and determine 
which participants or participant visits 
will be excluded.  This population w ill 
be analyzed as randomized. 
All PD analyses will be performed using 
the Modified Completer Population and all 
available post dose data; these will be the 
primary PD analyses.  Key PD analyses 
may be repeated on the Evaluable 
Population using all available post -dose 
data.  
Section 9.6 Maximum (peak) effect (Emax); calculated 
as maximum change from pre -dose 
response if pre -dose assessment is 
performed ; Maximum (peak) effect (Emax); 
calculated as maximum change from pre-
dose response if pre -dose assessment is 
performed; the neutral VAS point (50 for 
Drug liking, 0 for High) will be used as 
pre-dose response when VAS not 
performed or missing.  Clarification of how 
missing pre -dose 
VAS values will be 
handled  
Section 9.8 x A linear mixed-effects model that 
includes period, sequence, and treatment x A linear mixed-effects model that 
includes site, period, sequence, and 
treatment as fixed effects, and the Addition of “site” as 
a fixed effect in 
response to the 
PF-[ADDRESS_780490] w ill be 
used addition of a new 
investigator site  
Section 9.8.1 The changes from baseline will be analyzed 
with an analysis of variance (ANOVA) 
model consisting of: Sequence, Period, 
Treatment, Time, Period*Time and 
Treatment*Time terms as fixed effects, and 
a participant (Sequence) term as a random 
effect for. To accommodate the repeated 
measures aspect of the design, a compound 
symmetric covariance matrix will be 
employed, with the participant set to 
Period*Participant (Sequence).  The changes from baseline will be 
analyzed with an analysis of variance 
(ANOVA) model consisting of: Site, 
Sequence, Site*Sequence, Period, 
Treatment, Time, Period*Time, 
Site*Treatment and Treatment*Time 
terms as fixed effects, and a participant 
(Site*Sequence) term as a random effect 
for testing Site, Sequence, and 
Site*sequence effect. Si te*Treatment 
interaction will be evaluated and this 
interaction term will be dr opped from the 
final model if it is not significant. To 
accommodate the repeated measures 
aspect of the design, a compound 
symmetric covariance matrix will be employed, with the
 participant set to 
Period*Participant (Sequence).  Addition of “site” as 
a fixed effect in 
response to the 
addition of a new 
investigator site  
Section 9.8.[ADDRESS_780491] the change of 
Sponsor  
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 117 Section 10.4.2 Is a WOCBP and using a contraceptive 
method that is highly effective (with a 
failure rate of <1% per year), with low user 
dependency, as described below, during the 
intervention period and for at least [ADDRESS_780492] dose of study intervention, 
which corresponds to the time needed to 
eliminate any study intervention(s).  Is a WOCBP and using a contraceptive 
method, as described below, during the 
intervention period and for at least [ADDRESS_780493] dose of study intervention, 
which corresponds to the time needed to 
eliminate any study intervention(s).  Change to reflect the 
addition of further  
forms of acceptable 
female contraception, 
in order to facilitate 
subject enrollment 
Section 10.4.[ADDRESS_780494] Low 
User Dependency.  
1. Intrauterine device (IUD).  
2. Bilateral tubal occlusion. 
3. Vasectomized partner. 
x Vasectomized partner is a highly 
effective contraceptive method 
provided that the partner is the sole 
sexual partner of the woman of 
childbearing potential and the absence 
of sperm has been confirmed.  If not, 
an additional highly effective method 
of contr aception should be used.  The Female subjects of child-bearing potential 
must use at least one form of the following 
contraception methods.  
1. Intrauterine device (IUD).  
2. Bilateral tubal occlusion. 
3. Hormonal contraception. 
4. Contraceptive implants. 
5. Double-barrier method (any 
combination of physical and chemical 
methods). 
6. Confirmed infertility of sexual 
partner. Change to add further  
forms of acceptable 
female contraception, 
in order to facilitate 
subject enrollment 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 118 spermatogenesis cycle is 
approximately 90 days. 7. Engaged exclusively in a same-sex 
relationship. 
8. Total abstinence (periodic abstinence 
is not acceptable). 
9. Vasectomized partner. 
x Vasectomized partner is a highly 
effective contraceptive method 
provided that the partner is the sole 
sexual partner of the woman of 
childbearing potential and the absence 
of sperm has been confirmed.  If not, 
an additional method of contraception 
should be used.  The spermatogenesis 
cycle is approximately 90 days. 
 
PF-00345043 
Protocol A9451181 
Protocol V 5.0, 29 Apr 2022 
 
 
Viatris Specialty LLC CONFIDENTIAL 
Page 119 11. REFERENCES  
1 Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabal in and gabapentin. 
Drugs 2017; 77(4):403-26. 
2 Smith RV, Lofwall MR, Havens JR. Abuse and diversion of gabap entin among 
nonmedical prescription opi[INVESTIGATOR_591812]. A m J Psychiatry 2015; 
172(5):487-8. 
3 Wilens T, Zulauf C, Ryland D, et al. Prescription medication misuse among opi[INVESTIGATOR_591813]. Am J Addic t 2015; 24(2):173-7. 
[ADDRESS_780495] frequ ently involved in drug 
overdose deaths: [LOCATION_002], 2011-2016. Natl Vital Stat Rep 2018; 67(9):1-14. 
5 Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opi[INVESTIGATOR_2438],  and the risk of opi[INVESTIGATOR_2480] -
related death: a population-based nested case-control study. PL oS Med 2017; 
14(10):e1002396. 
6 Hakkinen M, Vuori E, Kalso E, et al. Profiles of pregabalin a nd gabapentin abuse by 
[CONTACT_591855]. Forensic Sci Int 2014; 241:1-6. 
7 Slavova S, M iller A, B unn TL, et al. Prevalence of gabapentin in drug overdose 
postmortem toxicology testing results. Drug Alcohol Depend 2018 ; 186(5):80-5. 
8 Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence, and  withdrawal. Ann 
Pharmacother 2016; 50(3):229-33. 
9 Bonnet U, Scherbaum N. [On the risk of dependence on gabapent inoids]. Fortschr 
Neurol Psychiatr 2018; 86(2):82-105. 
10 Neurotin®. Package Insert . Parke-Davis, Division of [COMPANY_007] Inc. [LOCATION_001], NY. 2020. 
11 Diazepam. Package Insert . Genentech [LOCATION_003], Inc. South San Francisco, CA. 2016. 
12 Vernau KM, LeCouteur RA. Anticonvulsant drugs. In: Maddison JE, Page SW, Church 
DB, editors. Small animal clinical pharmacology. 2nd ed. Edinbu rgh: W.B. Saunders; 
2008: p. 367-9. 
13 Busto U, Kaplan HL, Zawertailo L, et al. Pharmacologic effec ts and abuse liability of 
bretazenil, diazepam, and alprazolam in humans. Clin Pharmacol Ther 1994; 55:451-63.  
[ADDRESS_780496] 
1988;23(5)(May ):449-67. 
PF-[ADDRESS_780497], et al. Relative abus e liability of lorazepam 
and diazepam: an evaluation in 'recreational' drug users. Drug Alcohol Depend 1988; 
22:215-22. 
16 RR-MEMO 720-[ZIP_CODE]. Abuse Liab ility of Pregabalin (CI-1008) in Recreational 
Sedative/Alcohol Users. 09 May 2001. 
17 US Department of Health and Human Services, Food and Drug Ad ministration, Center 
for Drug Evaluation and Research (CDER). Assessment of abuse po tential of drugs. In: 
Guidance for industry. Silver Spring, MD: Food and Drug Adminis tration; 2017: 34 
pages. 
18 Schoedel KA, Szeto I, Setnik B, et al. Abuse potential asses sment of cannabidiol (CBD) 
in recreational polydrug users: a randomized, double-blind, con trolled trial. Epi[INVESTIGATOR_297047] 2018; 88(11):162-71. 
19 Eaton TA, Comer SD, Revicki DA, et al. Determining the clini cally important 
difference in visual analog scale scores in abuse liability stu dies evaluating novel opi[INVESTIGATOR_591814]. Qual Life Res 2012; 21(6):975-81. 
[ADDRESS_780498] drug and 
placebo in human abuse potential studies. J Biopharm Stat 2013; 23(2)(Mar):294-306. 